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ABSTRACT 
Improvements on Quantitative and Qualitative Analysis of 
Fetal Nucleic Acids in Maternal Plasma 
The currently available techniques for prenatal diagnosis, which rely on obtaining 
the fetal genetic materials through invasive means, are often associated with a 
significant risk of fetal loss. It would be ideal if these invasive procedures, such as 
chorionic villus sampling and amniocentesis, could be avoided. Thus, the discovery 
of circulating fetal nucleic acids in maternal plasma has opened up new possibilities 
for researchers to develop noninvasive tests that can potentially be provided as safer 
alternative in routine obstetric practices. 
Cell-free nucleic acids have been investigated extensively in many fields of research. 
With recent advancement in the potential use of circulating fetal nucleic acids, 
noninvasive prenatal diagnosis of fetal chromosomal aneuploidies and monogenic 
diseases was made feasible. However, prenatal assessment by maternal plasma 
analysis is still a challenge because fetal nucleic acids are present at low 
concentrations among a high maternal background. The coexistence of these minor 
ii 
and major nucleic acid populations has posed technical limitations in both the 
qualitative and quantitative analysis of circulating fetal nucleic acids. This thesis 
aims to investigate various analytical issues associated with fetal nucleic acid 
analysis in maternal plasma and to describe different strategies that were used to 
help overcome these challenges. 
A number of diagnostic applications have been developed based on circulating fetal 
RNA detection. Yet not all placental messenger RNA (mRNA) species in maternal 
plasma are abundant enough for reliable detection. The first part of this thesis 
focuses on the assessment of whole transcriptome preamplification technology as a 
potential means to increase the abundance of placental expressed mRNA markers in 
maternal plasma. For the profiling of multiple transcripts, it is essential that the 
entire RNA transcriptome is uniformly amplified by the reaction. mRNA expression 
profiling was performed in placental tissues with and without preamplification to 
evaluate if the original mRNA expression profile could be preserved after the 
procedure. Then, a serial dilution experiment was done to study the effect of RNA 
input on the degree of amplification. Finally, the feasibility of preamplifying 
maternal plasma RNA was investigated. The results showed that preamplification of 
placental RNA was successful even when the total RNA concentrations of the 
• • • 
111 
samples were as low as 1 ng/|iL. The original mRNA expression profile in placental 
tissues was also shown to be generally preserved after the reaction. In addition, RNA 
input was shown to be positively and significantly correlated to both the RNA output 
and the output/input ratio. Finally, preamplification of placenta expressed mRNA 
was shown to be feasible in both third and first trimester maternal plasma samples 
for transcripts with relatively high abundance. 
Gene dosage comparison is a strategy used for detecting fetal chromosomal 
aneuploidies, and it requires accurate and precise measurements to reflect the true 
dosage of the genes on different chromosomes. In the second part of the thesis, I 
investigated factors that may improve the accuracy of real-time polymerase chain 
reaction (qPCR) for quantitative measurements of fetal DNA in maternal plasma. 
The following preanalytical issues were addressed: (i) the influence of using 
common and different sets of primers for amplification of multiple loci on different 
chromosomes, (ii) the effects of using monoplex and multiplex real-time PGR 
formulations, (iii) the effects of incorporating calibration curves for template 
quantification in conventional real-time PGR as opposed to single molecule counting 
techniques, such as digital polymerase chain reaction (dPCR). The results showed 
that conventional qPCR performed in a multiplex formulation with the use of same 
iv 
set of primers could be as good as dPCR in analyzing relative gene dosages. 
In addition to the detection of chromosomal aueuploidies, prenatal diagnosis of 
monogenic diseases, such as p-thalassemia and cystic fibrosis, has also been 
challenging as they are frequently caused by point mutations. Current methods for 
maternal plasma analysis for such mutations, such as qPCR and mass spectrometry, 
are not 100% sensitive and specific in detecting the minor population of fetal DNA 
that differs from the background maternal DNA by one nucleotide. The third part of 
this thesis demonstrates the use of dPCR to improve the sensitivity and specificity in 
the qualitative detection of paternally inherited fetal point mutation in maternal 
plasma. The results showed that allelic discrimination between the wild type and the 
mutant alleles was achieved in various samples using dPCR. The assay was also 
confirmed to be specific for the detection of the hemoglobin E (HbE) mutation. 
Fetal genotypes for the HbE mutation were correctly classified in 28 of the 30 
maternal plasma cases. Using dPCR analysis, noninvasive prenatal detection of 
paternally inherited mutations was demonstrated in maternal plasma. 
This thesis not only addresses the technological refinements in current maternal 
plasma nucleic acid analysis, but also provides important information on improving 
V 
the qualitative and quantitative analysis of fetal nucleic acids in maternal plasma for 
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SECTION I: BACKGROUND 
1 
Background 
CHAPTER 1: PRENATAL TESTNG 
1.1. THE AIM 
Prenatal testing has become a routine practice in antenatal care with the aims to 
manage and monitor the well-being of both the mother and fetus throughout 
pregnancy, and to aid reproductive decision-making by the parents in the case of 
pregnancies affected by specific genetic conditions. By performing prenatal testing, 
parents can be informed of the detection or exclusion of certain morphological， 
structural, functional, chromosomal, and molecular defects in the fetus prior to birth 
(Papp and Papp, 2003). Prenatal testing is offered in two contexts, namely screening 
and diagnosis (Sailer and Canick, 2008). Prenatal screening is for diseases that are 
relatively common in the population, for example, Down Syndrome, which occurs at 
1 in 750 live births (Antonarakis et al.，2004); whilst the need for prenatal diagnosis 
is mainly for pregnancies at high risk of certain diseases, such as parents who are 
positive for the thalassemia or trisomy 21 (T21) screening. Currently, prenatal 
testing is offered as a multi-step process. A screening process that typically employs 
noninvasive methods to identify women of high risk is followed by a definitive 
diagnosis often involves invasive procedures that confirm or exclude the 
2 
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abnormalities (Hall et al.，2010). Prenatal testing is widely accepted and is important 
as it enables parents to make informed reproductive choices. 
3 
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1.2. INVASIVE PRENATAL DIAGNOSIS 
The currently available definitive methods for prenatal diagnosis, such as 
amniocentesis and chorionic villus sampling (CVS), which offer access to fetal 
genetic material through invasive means, are associated with risk of fetal loss 
(Mazza et al., 2007，Mujezinovic and Alfirevic, 2007). Amniocentesis, which can be 
performed between the 15出 and 18出 weeks of gestation (second trimester), involves 
the removal of amniotic fluid by the insertion of a needle through the abdominal 
wall into the uterus under the guidance of ultrasound and carries an approximate risk 
of miscarriage of 1% (Tabor et al., 1986). In comparison, CVS is performed during 
the first trimester, between the 10出 and 13出 weeks of gestation, by inserting a needle 
into the uterine wall to obtain a biopsy of chorionic villi. This technique has been 
available since the early 1980s (Wapner, 2005), and also poses the risk of fetal 
miscarriage (Mujezinovic and Alfirevic, 2007). 
After the invasive procedures, the fetal materials sampled are then cultured to obtain 
enough numbers of fetal cells for the direct assessment of the chromosomal status 
(Stranc et al., 1997) or other genetic analyses. In addition to T21 (Down syndrome), 
4 
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other trisomy pregnancies such as trisomy 13 (Patau syndrome) and trisomy 18 
(Edwards syndrome), with incidence rates of 1 in 5,000 and 1 in 6,000 live births 
(Chen et al” 2003，Carey, 2006), can be identified by conventional karyotyping 
(cytogenetic analysis) or rapid aneuploidy detection (DNA analysis) (de Jong et al., 
2010). Full karyotyping can also reveal other fetal abnormalities including 
chromosome polyploidy, chromosome translocation, and chromosome deletion and 
insertion. Other molecular analyses have also been developed over the years, such as 
fluorescence in situ hybridization (FISH) (Caine et al., 2005) and quantitative 
fluorescence polymerase chain reaction (QF-PCR) (Caine et al., 2005, Chitty et al., 
2006, Cirigliano et al., 2006, Ochshom et al., 2006), offering rapid analysis of the 
dosage of chromosomes of interest. Moreover, the DNA obtained can also be used 
for mutation analysis. 
Even with the definitive nature of these diagnostic techniques, the risk associated 
with them still makes the decision to use invasive prenatal diagnosis difficult for 
pregnant women (van den Berg et al., 2005). Ideally, noninvasive prenatal screening 
could risk-stratify pregnant women prior to undergoing invasive procedures. 
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1.3. NONINVASIVE PRENATAL SCREENING 
While the dilemma remains that invasive prenatal diagnosis carries an inherent 
procedure-related risk (Mujezinovic and Alfirevic, 2007); noninvasive prenatal 
screening, such as ultrasonography and maternal serum biochemical screening, can 
be used to identify a subset of patients whose inherent risk is great enough to 
warrant diagnostic follow up while not subjecting patients at low risk to unnecessary 
diagnostic procedures (Cuckle and Wald, 1984). An effective screening should be 
directed only toward conditions that are clinically significant and prevalent in the 
population (Sailer and Canick, 2008). Given the increasing incidence of Down 
syndrome pregnancy (Resta, 2005), various screening programs have been 
developed. An optimal screening test should have a high detection rate and a low 
false-positive rate (less than 5% is desirable) (Sailer and Canick, 2008). 
One of the ways to screen for fetal Down syndrome is by ultrasonography. 
Ultrasound scanning can provide information of the anatomy of the fetus (Akgun et 
al., 2007). Increased nuchal edema was first reported by Brohnstein in a case of fetal 
Down, syndrome in the late first trimester pregnancy in 1989 (Sailer and Canick, 
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2008). In 1992，nuchal translucency (NT) was demonstrated as a marker for the 
assessment of risk for fetal Down syndrome (Nicolaides et al.，1992). NT is the 
measurement of the thickness of the subcutaneous fluid at the back of the neck of 
the fetus. The combination of maternal age and NT provide a detection rate of 77% 
at 5% false-positive rate (Snijders et al., 1998). 
Another way to assess risk of T21 is by maternal serum biochemical screening. The 
second trimester triple test measures the maternal serum levels of alpha-fetoprotein 
(AFP), human chorionic gonadotrophin (hCG), and unconjugated estriol (UE3), 
which gives a 66% detection rate for Down syndrome with a 4.5% false positive rate 
(Cuckle, 1996, Graves et al., 2002). With the addition of a fourth marker, inhibin-A, 
the quadruple test gives a detection rate of 75% at 5% false-positive rate (Wald et al., 
2003). If screened positive by the second trimester maternal serum biochemical tests, 
the pregnancy will be referred for amniocentesis. However, it would be desirable to 
conduct screening earlier in the pregnancy because one could opt for CVS as a 
means for definitive diagnosis. In addition, pregnancy termination is safer during 
early than late pregnancy (Sailer and Canick, 2008). 
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Of the maternal serum markers used in the second trimester screening, only the free 
beta subunit of hCG (P-hCG) was found to be useful between the 10出 and 13出 
gestational weeks to provide information about the risk of fetal Down syndrome 
(Wald et al.，1998). In addition to P-hCG, the first trimester maternal serum 
screening program uses another serum biochemical marker, pregnancy-associated 
plasma protein A (PAPP-A) (Krantz et al.，1996)，in combination with maternal age 
and fetal NT measurement to assess the risk of fetal trisomies. The detection rate for 
Down syndrome was 86% and for trisomy 13/18 was 100% at a false-positive rate of 
6.7% (Spencer et al., 2000). The performance of first trimester combined test was 
evaluated in four clinical studies: the NIH-fUnded Blood, Ultrasound, Nuchal (BUN) 
study, the one-stop clinic to assess risk (OSCAR) in the UK, the Serum, Urine, 
ultrasound Study (SURUSS) in the UK, and the First and Second Trimester 
Evaluation of Risk (FASTER) in the US. The four studies together give an average 
detection rate of 85%, which is slightly better than the second trimester quadruple 
screening test (Sailer and Canick, 2008). 
In spite of the advances in the approaches for noninvasive prenatal screening, they 
are still essentially measuring epiphenomena associated with chromosomal 
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aneuploidies, restricting the gestational window for which the test can be applied 
(Lo and Chiu, 2008). In addition, due to this indirect nature, many markers are not 
robust enough to be a stand-alone test (Lo, 2009). Despite the high sensitivity and 
specificity with the use of multiple markers (Malone et al.，2005), these noninvasive 
methods still remain as screening tests and are associated with a not insignificant 
false positive rate. Subsequent invasive procedures are still needed for a definitive 
diagnosis if a woman is screened positive. The ultimate goal is to develop a true 
noninvasive diagnostic test. 
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CHAPTER 2: NONINVASIVE PRENATAL DIAGNOSIS 
2.1. CIRCULATING FETAL CELLS IN PRENATAL DIAGNOSIS 
One possibility for developing a true noninvasive prenatal diagnostic test is to detect 
the core pathology of the fetus by analyzing the fetal genetic materials directly. 
Many investigators have evaluated different approaches to isolate fetal nucleated 
cells from maternal blood for molecular cytogenetic analysis (Herzenberg et al, 
1979, Bianchi et al., 1990, Cheung et al., 1996). The presence of fetal cells in 
maternal circulation was first discovered in 1893, where multinucleated trophoblasts 
were detected in the lungs of 17 women who died from eclampsia (Schmorl, 1893， 
Lapaire et al., 2007). The discovery was confirmed by modem molecular analysis 
(Johnson and Bianchi, 2004). 
However, fetal nucleated cells are very rare in the maternal circulation. It was 
reported that there were only 2 fetal cells among 770,000 maternal cells from 
maternal blood samples in early gestation (Hamada et al., 1993). In addition, 
circulating fetal cells were also shown to persist in the maternal circulation after 
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delivery (Bianchi et al., 1996)，which may interfere with the diagnosis of future 
pregnancies (Iyer et al., 2003). In 2002，a multicenter trial reported a sensitivity of 
41% for detecting male fetal cells in maternal blood with a false-positive rate of 
11.1% (Bianchi et al., 2002). Therefore, despite their potential in the detection of 
single gene disorders (Cheung et al., 1996) and chromosomal aneuplodies (Bianchi 
et al , 1997), circulating fetal cells have limited practicality in noninvasive prenatal 
diagnosis (NIPD) with the current technologies. 
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2.2. CIRCULATING FETAL NUCLEIC ACIDS IN PRENATAL DIAGNOSIS 
During fetal cell isolation, cell-free plasma was often discarded. The detection of 
cell-free nucleic acids from human plasma was first described in 1948. It was 
reported that DNA and RNA could be detected in the plasma of both healthy and 
sick individuals (Mandel and Metais, 1948). Since then, many investigations have 
been done to exploit the clinical values of circulating nucleic acids. In the late 1970s, 
the clinical potential of circulating nucleic acids for cancer detection was first 
demonstrated when higher levels of serum DNA was found in cancer patients than 
patients with non-malignant diseases (Leon et al., 1977b). This remarkable finding 
was soon followed by the other reports of plasma detection of tumor-derived DNA 
in cancer patients (Stroun et al., 1989, Sorenson et al” 1994，Vasioukhin et al., 1994). 
In 1997, recognizing the pseudomalignant nature of the human placenta, Lo et al. 
discovered the existence of circulating fetal DNA in maternal plasma by detecting Y 
chromosome-specific DNA sequences in the plasma of pregnant women (1997). The 
relative abundance of circulating fetal DNA compared to circulating fetal cells has 
revealed its potential for developing NIPD (Lo et al., 1998b). Before long, the 
presence of cell-free fetal RNA in maternal plasma was also reported (Poon et al., 
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2000). Circulating fetal RNA represents a new class of universal fetal nucleic acid 
markers that are fetal gender- and polymorphism-independent, which gives them 
certain advantages over DNA markers as they can be applied to all pregnant women. 
Together, the discoveries of circulating fetal nucleic acids have opened up new 
possibilities for NIPD. 
In March 2004，the Special Noninvasive Advances in Fetal and Neonatal Evaluation 
(SAFE) network was initiated in Europe. SAFE is a Network of Excellence 
established under the European Commission Sixth Framework Programme to 
implement routine, cost-effective NIPD and neonatal screening through the creation 
of long-term partnerships within and beyond the European community. The network 
covers primary scientific research, ethics, psychosocial and socio-economic areas. In 
scientific research, the network has played a major role in standardizing noninvasive 
procedures，such as rhesus D (RhD) genotyping and DNA extraction protocol 
(Legler et al., 2007). To date, SAFE has 50 partners across Europe, the Middle East 
and India (Maddocks et al., 2009). 
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2.3. CIRCULATING FETAL DNA IN MATERNAL PLASMA 
2.3.1. Biology of circulating fetal DNA 
After successful detection of cell-free fetal DNA in maternal plasma for the first 
time in 1997，much has been understood about its biology in the past decade. It has 
been suggested the cell-free fetal DNA originates from placental trophoblast cells 
(Flori et al., 2004，Alberry et al•，2007) and is released into the maternal circulation 
via apoptosis (Sekizawa et al” 2000, van Wijk et al., 2000, Kolialexi et al , 2001). 
Considering the rarity of circulating fetal cells, approximately one fetal cell in one 
milliliter of maternal blood (Bianchi et al., 1997), it is reasonable to believe that 
circulating fetal cells are not the predominant source of cell-free fetal nucleic acids 
in maternal plasma. In one milliliter of maternal plasma, cell-free fetal DNA 
amounts to a mean quantity of 25.4 genome-equivalents (GE) in early gestation and 
even reaches to 292.2 GE at full-term, accounting for a mean percentage of 3.4% -
6.2% of total plasma DNA (Bianchi, 1998，Lo et al.，1998b). The level of fetal DNA 
was also shown to increase proportionally as gestation progresses (Lo et al., 1998b). 
Fetal DNA in maternal circulation was detectable as early as the 5th week of 
gestation (Honda et al., 2002) and even at day 18 after embryo transfer by assisted 
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reproduction (Guibert et al., 2003). Unlike circulating fetal cells, circulating fetal 
DNA does not persist after pregnancy (Johnson-Hopson and Artlett, 2002, Smid et 
al , 2003) and is rapidly cleared from the maternal circulation after delivery with an 
apparent half-life of 16.3 minutes (Lo et al., 1999d), minimizing any possible 
interference between pregnancies. 
2.32. Clinical applications of circulating fetal DNA 
The clinical applications of circulating DNA was first revealed in the late 1960s 
when high levels of circulating DNA was observed in the serum of patients with 
systemic lupus erythematosus (Tan et al., 1966). Before long, this new approach of 
using plasma or serum DNA for noninvasive diagnosis was applied to various 
clinical conditions, including rheumatoid arthritis (Koffler et al., 1973, Leon et al., 
1977a), pulmonary embolism (Barada et al., 1980)，and hemodialysis (Steinman and 
Ackad, 1977). As mentioned, the clinical potential of circulating nucleic acids for 
cancer diagnosis and prognosis was first demonstrated in the late 1970s. Since then, 
there has been a growing interest in extending the applications of circulating DNA to 
other fields of study, including prenatal diagnosis, monitoring of trauma (Lo et al., 




The clinical applications of circulating DNA for NIPD or monitoring involve 1) 
qualitative plasma detection of fetal-specific polymorphisms or mutations in the 
fetal-specific sequence or 2) quantitative detection of aberrant concentrations of 
plasma DNA in pregnancy-associated disorders (Lo and Chiu, 2007). 
2.3.2.1. Qualitative analysis of fetal DNA in materna l plasma 
Initially, researchers focused on the qualitative detection of genetic loci that are 
inherited from the father, but are absent in the mother, such as DNA sequences 
originated from the Y-chromosome in pregnant women carrying male fetuses (Lo et 
al., 1998b), or RhD sequences in the plasma of RhD-negative women pregnant with 
RhD-positive fetuses (Faas et al., 1998，Lo et al., 1998a). Currently, noninvasive 
determination of fetal RhD status (Costa et al , 2002b, Finning et al., 2002), and 
prenatal gender assessment for sex-linked diseases (Costa et al., 2002a) and 
congenital adrenal hyperplasia (Rijnders et al., 2001) have been well established and 
translated into routine practice (Maron and Bianchi, 2007). High accuracy of 
16 
Background 
noninvasive maternal plasma analysis for RhD status was also confirmed (Wang et 
al., 2009，Gutensohn et al” 2010). 
For diagnostic purposes, the same strategy was also used in the prenatal detection or 
exclusion of monogenic diseases. By detecting the presence or absence of paternally 
inherited mutations in maternal plasma, for example, a positive detection for 
autosomal dominant diseases, such as achondroplasia (Saito et al., 2000), myotonic 
dystrophy (Amicucci et al., 2000)，and Huntington disease (Gonzalez-Gonzalez et 
al., 2003); or a negative detection for autosomal recessive diseases, such as 
P-thalassemia (Chiu et al., 2002b, Ding et al., 2004), congenital adrenal hyperplasia 
(Rijnders et al., 2001, Chiu et al., 2002a), cystic fibrosis (Gonzalez-Gonzalez et al., 
2002) and hemoglobin E disease (Fucharoen et al., 2003，Tsang et al., 2007), NIPD 
of single gene disorders is in principle achievable. 
2.3.2.2. Quantitative analysis of fetal DNA in mate rna l plasma 
In addition to qualitative analysis of fetal DNA in the maternal circulation, the 
possibility of quantitative aberrations in pathologic pregnancies was also explored. 
The quantitative detection of aberrant concentration of circulating fetal DNA was 
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largely based on the use of Y chromosomal markers. Using real-time quantitative 
polymerase chain reaction (qPCR) assays, increased levels of circulating fetal DNA 
was noted in the maternal plasma or serum of pregnant women with preeclampsia 
(PET) relative to normal pregnant women (Lo et al., 1999c, Zhong et al., 2001b), 
Such elevation was also observed prior to the onset of symptoms (Zhong et al , 
2001a，Zhong et al., 2002) and was shown to correlate with the severity of the 
disease (Zhong et al , 2001b). Other studies have demonstrated the quantitative 
utility of circulating fetal DNA in detecting fetal chromosomal aneuploidies, 
particularly in diagnosis of fetal Down syndrome, where a 2-fold increase of fetal 
DNA concentration was reported in the plasma of women pregnant with T21 fetuses 
relative to normal pregnant women (Lo et al., 1999b). For other aueuploidies, 
elevation of cell-free fetal DNA has been found in trisomy 13 (Wataganara et al , 
2003), but not in trisomy 18 (Zhong et al., 2000a, Wataganara et al., 2003). 
Quantitative aberrations of circulating fetal DNA have also been reported in other 
pregnancy-associated complications, including polyhydramnios (Zhong et al., 
2000b), fetomatemal hemorrhage (Lau et al., 2000), hyperemesis gravidarum 
(Sekizawa et al., 2001)，invasive placentation (Sekizawa et al , 2002), intrauterine 
growth restriction (Caramelli et al., 2003), preterm labor (Leung, 1999，Farina et al, 
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2005), and ectopic pregnancies (Lazar et al., 2006). 
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2. 4. CIRCULATING FETAL RNA IN MATERNAL PLASMA 
Circulating fetal RNA in maternal plasma represents another class of universal fetal 
nucleic acid marker for NIPD. Similar to circulating DNA, the clinical potential of 
circulating RNA was first revealed in cancer studies. In 1999, Lo et al. observed the 
presence of circulating Epstein-Barr virus-associated RNA in the plasma of 
nasopharyngeal carcinoma patients, which prompted the later search for circulating 
fetal RNA in maternal plasma (Lo et al” 1999a). 
2A.1. Biology of circulating fetal RNA 
The presence of fetal-derived RNA was first demonstrated in 2000 by the detection 
of zinc finger protein mRNA specific for the Y chromosome in maternal plasma 
(Poon et al., 2000). Similar to plasma fetal DNA, it has been suggested that 
circulating fetal RNA also originates from the placenta, as placenta-derived mRNA 
transcripts, such as chorionic somatomammotropin hormone 1 (human placental 
lactogen) {CSHl, alias hPL), P-hCG, and corticotrophin-releasing hormone {CRH), 
have been detected in maternal plasma (Ng et al , 2003a, Ng et al” 2003b). A 
unidirectional transfer of placenta RNA from the placenta to the maternal circulation 
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has also been demonstrated (Ng et al., 2003b), and such RNA is cleared rapidly 
postpartum with a median half-life of 14.1 min (Chiu et al., 2006). 
The discovery of circulating RNA was rather surprising considering the well known 
instability of RNA; however，circulating fetal RNA was later on shown to be 
unexpectedly stable (Tsui et al., 2002). It has been proposed that a large proportion 
of plasma RNA is associated with filterable subcellular particles (Ng et al., 2002) 
suggested to be apoptotic bodies (Halicka et al., 2000, Hasselmann et al., 2001) or 
syncytiotrophoblast microparticles (Gupta et al., 2004), which might protect them 
from RNase degradation (Tsui et al., 2002). Circulating fetal mRNA can be readily 
detected in maternal plasma as early as the 4th week of gestation (Chiu et al., 2006). 
This is one week earlier than the earliest gestational age when plasma fetal DNA can 
be detected (Honda et al., 2002, Rijnders et al., 2001)，showing potential for the 
development of early NIPD. In contrast to plasma fetal DNA, where the 
concentration increases as pregnancy progresses (Lo et al., 1998b), plasma mRNA 
levels have been shown to correlate with the variation in the corresponding protein 
product levels (Ng et al., 2003b, Ge et al , 2005) or the corresponding gene 
expression profiles in the placenta during pregnancy (Tsui et al., 2004). 
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2A.2. Clinical applications of circulating fetal RNA 
Circulating plasma RNA has certain advantages over the analysis of circulating fetal 
DNA. First, each tissue type in the body has its own characteristic mRNA profile; by 
targeting a tissue type that is only present in the fetus, RNA markers can be 
fetal-specific, yet fetal gender- and polymorphism-independent. Second, multiple 
mRNA products are generated from each active gene; such intrinsic amplification 
effect might provide RNA markers higher sensitivities over DNA markers (Lo, 
2009). Most importantly, markers can be engineered to exploit disease-specific gene 
expression patterns for pregnancy-associated disorders (Tsui et al., 2004). 
2.4.2.1. Quantitative analysis of fetal RNA in mate rna l plasma 
Detection of quantitative aberrations of circulating fetal mRNA transcripts has also 
been found to be a promising approach for prenatal diagnosis. In the study of PET, 
plasma CRM mRNA has been reported to be elevated by 10.5-fold in preeclamptic 
pregnancies, compared with non-preeclamptic pregnancies matched for gestational 
age (Ng et al., 2003a). Considering the 5-fold increase in fetal DNA previously 
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observed in PET (Lo et al., 1999c)，fetal RNA in maternal plasma might be a better 
molecular marker than fetal DNA for PET. Maternal plasma CRH mRNA has also 
been linked to disease severity (Farina et al., 2004) and has shown more pronounced 
elevation in early-onset PET (Zhong et al., 2005a). In a recent study, a panel of 
novel mRNA markers was identified for the prenatal assessment of PET. By 
detecting quantitative aberrations of these markers in asymptomatic pregnant 
women who subsequently developed PET, disease occurrence could potentially be 
predicted (Purwosunu et al., 2009). 
In 2003, maternal plasma detection of a panel of chromosome 21-encoded mRNA 
sequences of placental origin was demonstrated between the 9也 and 13山 weeks of 
pregnancy (Oudejans et al., 2003), implicating the potential of circulating fetal RNA 
as an alternative molecular marker for early prenatal diagnosis of Down syndrome. 
Since then, researchers were prompted to further expand the search for other usable 
markers. In 2004，placenta expressed transcription factor mRNA was shown to be 
detected in maternal plasma (Go et al., 2004). In the same year, using a 
microarray-based method, Tsui et al systematically studied the gene expression 
profiles in the human placenta，and identified a list of pregnancy-specific transcripts 
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that could be detected in maternal plasma for the development of novel plasma RNA 
markers (Tsui et al., 2004). 
In a preliminary investigation of the feasibility of circulating placental RNA for fetal 
chromosomal aneuploidy detection, Ng et al. has shown that the maternal serum 
concentration of p-hCG mRNA was significantly reduced by 9.4-fold in women with 
trisomy 18 pregnancies and mildly elevated by 2.2-fold in women with T21 
pregnancies (Ng et al” 2004). In 2007, a placenta-specific transcript from 
chromosome 21, placenta-specific 4 (PLAC4) mRNA, was identified using 
microarray and was shown to be detectable in maternal plasma with rapid clearance 
after delivery (Lo et al., 2007b). Using such RNA species, Lo et al. demonstrated the 
feasibility of using a placenta-specific mRNA transcript in detecting fetal 
chromosomal aneuploidy noninvasively. By analyzing ratio of the heterozygous 
allele of a single nucleotide polymorphism (SNP) on the PLAC4 mRNA, the SNP 
ratios were compared between euploid and trisomic pregnancies using mass 
spectrometry, yielding a sensitivity of 90% and a specificity of 96% for fetal T21 
detection (Lo et al., 2007b). 
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Quantitative aberrations of fetal RNA have also been reported in other 
pregnancy-associated pathologies, such as preterm delivery (Zhong et al., 2005b) 
and gestational trophoblastic diseases (Masuzaki et al., 2005). Together, these 
findings have illustrated the potential diagnostic value of circulating fetal RNA in 
maternal plasma by quantitative analyses. 
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CHAPTER 3: TECHNICAL CHALLENGES IN ANALYZING CIRCULATING FETAL 
NUCLEIC ACIDS 
3.1. INTRODUCTION 
Analysis of circulating nucleic acids has been applied to many fields of study, 
including prenatal diagnosis (Lo and Chiu, 2007, Maron and Bianchi, 2007), cancer 
research (Garcia-Olmo et al., 2004, Goebel et al , 2005，O'Driscoll, 2007)， 
transplantation medicine (Lo et al.，1998c)，and critical care medicine (Chiu et al., 
2005b, Rainer and Lam, 2006). Serum samples have conventionally been used in 
proteomics; however, detection of circulating nucleic acids in serum samples are 
also commonly reported (Leon et al., 1977b, Nawroz et al., 1996，Kopreski et al , 
1997，Lo et al., 1997). In prenatal diagnosis, the detection of cell-free fetal nucleic 
acids in maternal blood is technically challenging. The difference between maternal 
plasma and maternal serum is highlighted by the higher amount of maternal 
background DNA in the latter. Cell-free fetal nucleic acids are present in low 
abundance in the maternal circulation; therefore, interference from the 
overwhelming maternal background may become problematic during analysis. 
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It has been demonstrated that the level of fetal DNA remains relatively constant in 
the maternal blood while the total genomic DNA content is significantly lower in 
plasma than serum (Lee et al., 2001). Such a finding is suggested to be related to the 
lesser degree of lysis of maternal blood cells due to the absence of clotting in plasma, 
causing less ex vivo release of DNA from maternal leucocytes (Lui et al., 2002). It is 
also reported that the fractional fetal DNA concentration has shown a 20-fold 
enrichment using maternal plasma for DNA extraction compared to maternal serum 
(Lo et al., 1998b). However, even with these comparative advantages of using 
maternal plasma, many technical challenges still lie within the use of maternal 
plasma analysis for NIPD. 
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3.2. PREANALYTICAL ISSUES IN MATERNAL PLASMA NUCLEIC ACID ANALYSIS 
3.2.1. Low abundance of cell-free fetal nucleic acids in maternal plasma 
The rarity of fetal nucleic acids in maternal plasma may pose potential risks of 
generating false negative results, which may lead to false reassurance and possibly 
fetal mortality if treatments have not been instituted in a timely manner (Finning et 
al., 2008). With the already low level of fetal nucleic acids in maternal plasma, any 
loss of genetic materials during experiments may further lead to false negative 
results. Therefore, preanalytical parameters such as the type of anticoagulants, 
processing protocols, storage conditions, and extraction methods should be 
optimized to maximize the absolute concentrations of the fetal nucleic acids. 
The choice of anticoagulants is an important parameter in DNA recovery. 
Anticoagulants, such as ethylenediaminetetraacetic acid (EDTA), citrate and heparin, 
help maintain fetal DNA concentration in delayed blood processing (Lam et al , 
2004). It has been reported that EDTA has better efficacy in preserving the fetal 
DNA concentration if plasma separation is delayed until 24 hours of venesection 
(Lam et al., 2004). In addition, different extraction protocols should be used for 
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different classes of molecular markers. For fetal DNA, a higher DNA recovery has 
been shown using a column-based extraction method; while a magnetic-bead based 
extraction method has been shown to recover fetal RNA at a higher concentration 
(Chiu et al., 2005a). The development of commercially available automated 
extraction machines has also provided an efficient and reliable manner for nucleic 
acid extraction. To develop a standardization process for extraction of fetal DNA in 
maternal plasma, an international workshop was conducted to evaluate different 
manual and automated DNA extraction methods. The best results were obtained 
with the QIAamp DSP Vims Kit followed by the QIAamp DNA Blood Mini Kit 
(Legler et al., 2007). In addition to sample preparations, innovative assay designs 
exploiting the physical characteristics of the fetal nucleic acids can also improve the 
fractional fetal concentration through selective enrichment. Circulating fetal DNA 
exists in the maternal plasma mainly in the form of short DNA fragments (Chan et 
al., 2004); size fractionation by selectively targeting the shorter DNA molecules in 
the maternal plasma has been shown to improve the relative proportion of the fetal 
DNA (Li et al., 2004b). Similarly, circulating fetal RNA is partially degraded in the 
maternal plasma with a preponderance of 5' mRNA fragments (Wong et al.，2005). 
By specifically targeting the more abundant 5’ ends of the mRNA species, higher 
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detection sensitivity may be achieved. Besides the above mentioned physical 
enrichment techniques, investigators have also explored other chemical means to 
enrich the amount of fetal nucleic acids prior to analysis; protocols such as adding 
more TRIzol LS when preparing RNA samples (Heimg et al., 2009) or using 
commercially available whole genome or transcriptome amplification kits for both 
DNA and RNA analyses have been proposed. 
3.2.2. High level of maternal background in maternal plasma 
The fractional fetal DNA concentration in maternal plasma is dependent on the 
relative proportions of both the fetal and the maternal DNA components. 
Theoretically, the accuracy and reliability of fetal nucleic acid detection can be 
enhanced by increasing the fractional fetal DNA concentration through the 
suppression of the maternal background (Lo and Chiu, 2008). 
It has been demonstrated most of the DNA in plasma is hematopoietic in origin (Lui 
et al., 2002). Therefore it is reasonable to postulate that the majority of the maternal 
nucleic acid in maternal plasma might also originate from the maternal 
hematopoietic cells (Tsui et al , 2004, Chim et al., 2005). To minimize any additional 
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release of maternal DNA, precautions should be taken to prevent any lysis of the 
maternal hematopoietic cells. During plasma separation, optimization of the 
centrifugation protocol is essential to ensure the process is gentle enough to prevent 
lysis of maternal leucocytes but yet vigorous enough to generate acelluar plasma 
(Chiu et al., 2001b). Inadequate processing may generate false positive results due to 
the detection of residual circulating fetal cells as indicated by reports of apparent 
persistence of fetal DNA in maternal plasma postpartum (Invemizzi et al, 2002). 
Chiu et al. have demonstrated a two-step processing protocol with 16000 g 
centrifugation is effective in providing acellular plasma (2001b). Dhallan et al. have 
also shown that the addition of formaldehyde to maternal plasma could enrich fetal 
DNA up to 7-fold, possibly through the stabilization of maternal leucocytes thus 
preventing maternal DNA liberation (2004). However, these findings were not 
reproduced by other groups (Chinnapapagari et al., 2005, Chung et al., 2005b). One 
of the possible explanations for this discrepancy is the imprecise nature of the 
technique used by Dhallan et al. for estimating the fractional fetal DNA 
concentration. Imprecise analysis might cause an overestimation on the percentage 
of fetal DNA recovered from the maternal circulation (Chung et al.，2005a). 
Therefore, accurate measurements of fetal nucleic acids in maternal plasma are 
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essential in quantitative analysis. 
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3.3. ANALYTICAL ISSUES IN MATERNAL PLASMA NUCLEIC ACID ANALYSIS 
3.3.1. Imprecise measurement of fetal nucleic acid quantity 
Identification of fetal chromosomal aneuplodies, such as T21 (Down syndrome), 
trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X 
(Turner syndrome) in females, are common reasons why women opt for prenatal 
diagnosis. Down syndrome, being the most prevalent aneuploidy (Sherman et al., 
2007), is caused by the inheritance of three instead of two copies of chromosome 21. 
To detect the genetic pathology of a trisomy pregnancy, the most direct way is to 
determine the dosages of the potentially aneuploid chromosomes in the fetal genome 
quantitatively (Chiu et al., 2009). 
Since direct quantification of fetal DNA concentrations in maternal plasma cannot 
robustly distinguish trisomy pregnancies from normal pregnancies (Lo et al., 1999b), 
one approach is to perform chromosome dosage comparison. Theoretically, the 
additional copy of chromosome 21 in a T21 fetus would contribute an additional 
dose of DNA sequences released from chromosome 21 into the maternal circulation. 
This small additional amount of fetal DNA will result in a slight overrepresentation 
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of chromosome 21 relative to other chromosomes in the genome which may be 
detectable quantitatively. By quantifying fetal DNA sequences derived from 
chromosome 21 with comparison to a reference chromosome in maternal plasma, a 
polymorphism-independent test for fetal Down syndrome would be developed (Lo 
et al , 2007a). 
The detection of this small degree of quantitative difference however is quite 
technically challenging. First, fetal DNA in maternal plasma is cell-free; therefore 
methods such as FISH could not be applied for the determination of chromosome 
dosages in the fetal genome (Chiu et al., 2009). Second, since a fetal allele inherited 
from the mother is essentially the same as the background maternal DNA; 
chromosome dosage comparison can only be made in the total genome (i.e., 
maternal genome plus fetal genome). Third, only a mean of 10% of the DNA in 
maternal plasma is derived from the fetus (Lun et al.，2008a)，and the rest being an 
overwhelming excess of maternal-derived DNA. This further dilutes the genetic 
information one can obtain for the fetus through maternal plasma analysis, making 
the detection of any quantitative differences in fetal genome caused by the 
aneuploidy extra difficult. 
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Here, I provide an example to illustrate how small the degree of a quantitative 
difference that needs to be detected by an analytical method so that the diagnosis of 
fetal T21 is feasible. A maternal plasma sample from a euploid pregnancy containing 
50 GEs per milliliter of total DNA with 5 GEs per milliliter of DNA contributed by 
the fetus (i.e., 10% fetal DNA) should contain a total 100 copies (90 maternal copies 
plus 10 fetal copies) of chromosome 21 sequences per milliliter of maternal plasma. 
For a T21 pregnancy, each fetal GE would contribute three copies of chromosome 
21，resulting in a total of 105 copies (90 maternal copies plus 15 fetal copies) of 
chr21 sequences per milliliter of maternal plasma. At 10% fetal DNA concentration, 
the amount of chromosome 21-derived sequences in the maternal plasma of a T21 
pregnancy would therefore be 1.05 times that of a euploid case (Lo et al., 2007a). 
qPCR is a powerful analytical platform widely used for DNA quantification in 
maternal plasma. Using qPCR, relative concentrations of DNA are determined by 
plotting fluorescence against PCR cycle number on a log scale. Amounts of DNA 
are then quantified by comparing the data to a standard curve generated by serial 
dilutions of a known amount of DNA. Conventional qPCR can easily detect a 
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difference of one or more threshold cycles (the number of cycles required for a 
reaction to produce enough fluorescent signals to reach a certain fluorescent 
threshold), i.e. a minimum of 2-fold quantitative difference in the template DNA 
concentrations (Chiu et al.，2001a). This is not discriminatory enough to detect the 
additional chromosome 21 DNA sequences in a T21 maternal plasma sample. 
Through DNA quantification, Zimmermann et al. were able to attain a 1.5-fold 
discrimination power with qPCR for gene dosage assessment of a chromosome 21 
locus and a reference locus in aminocyte cultures in T21 fetuses (Zimmermann et al., 
2002). To achieve finer degrees of quantitative discrimination for gene dosage 
comparison, analytical factors affecting the precision of qPCR need be addressed. 
3.3.2. Coexistence of fetal nucleic acids and maternal nucleic acid background in 
maternal plasma 
In addition to the inadequate precision for quantitative measurements of circulating 
fetal nucleic acids, qualitative detections of fetal genetic materials in maternal 
plasma are also technically challenging. Since fetal DNA represents only a small 
fraction of all DNA in maternal plasma and it is masked by the maternal background 
DNA, the scope of NIPD was initially limited to the detection of paternally inherited 
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DNA sequences, such as SRY sequences and RhD gene in RhD-negative women 
(Bustamante-Aragones et al., 2010). However, plasma detection of other paternally 
inherited DNA sequences, particularly small DNA sequence differences, such as 
fetal point mutations and SNP alleles, is still technically difficult (Gibson, 2006). 
Unlike NIPD of fetal chromosomal aneuploidies, which typically involves the 
quantitative assessments of chromosome dosage imbalances (Lo et al•’ 2007a); 
NIPD of monogenic diseases relies on the qualitative detection of fetal genetic 
features in maternal plasma. A monogenic disorder is caused by a mutation or 
alteration in a single locus or gene in one or both members of a gene pair, and is 
transmitted following the laws of Mendelian inheritance. Traditional modes of 
inheritance include autosomal dominant, autosomal recessive, and sex-linked. Other 
patterns of inheritance include mitochondrial inheritance, uniparental disomy, 
imprinting, and trinucleotide repeat expansion (Guttmacher and Collins, 2002). 
NIPD of monogenic diseases typically relies on the detection of paternally inherited 
fetal alleles or mutations in maternal plasma (Tsang and Lo, 2007). Unlike the 
maternally inherited genetic traits, paternally inherited alleles are fetal specific in 
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maternal plasma as they are not shared by the maternal genome and are 
distinguishable from the background maternal DNA. In the case of autosomal 
dominant diseases, where a fetus has to inherit only one copy of a mutant allele from 
either the father or the mother to develop the disease phenotype, a positive detection 
of the paternally inherited mutant allele suggests the inheritance of the paternally 
transmitted disease in the fetus. However, this strategy cannot identify maternally 
inherited autosomal dominant diseases (Chiu et al., 2002b). Prenatal testing has 
been successfully achieved in achondroplasia (Saito et al., 2000), myotonic 
dystrophy (Amicucci et al., 2000)，and Huntington's disease (Gonzalez-Gonzalez et 
al., 2003). The same approach can also be used in the case of autosomal recessive 
diseases, where a fetus has to inherit both mutant alleles from the mother and the 
father in order to manifest the disease phenotype. Positive paternal mutation 
detection indicates the fetus could be either a carrier or a compound heterozygote, 
while a negative detection signifies prenatal exclusion of disease. Prenatal 
exclusions of congenital adrenal hyperplasia (Chiu et a l , 2002a), cystic fibrosis 
(Gonzalez-Gonzalez et al., 2002) and P-thalassemia (Chiu et al., 2002b, Ding et al., 
2004) have been achieved. 
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Despite the successful examples discussed above, qualitative detection of paternally 
inherited alleles in maternal plasma is still difficult as monogenic diseases are 
frequently caused by point mutations. For example, P-thalassemia, a disorder caused 
by mutations on the hemoglobin, beta gene (HBB) on chromosome 11 results in the 
reduction of p-globin synthesis; the majority of disease-causing mutations are single 
nucleotide substitutions, or deletions or insertions leading to frameshift (Weatherall, 
2004). Therefore, to diagnose p-thalassemia prenatally, one must develop an 
analytical technique that is able to sensitively and specifically detect single 
nucleotide changes, such as fetal-specific point mutations or SNP alleles linked to 
the disease locus (Ding et al.，2004). However, the coexistence of fetal DNA and 
maternal background DNA in maternal plasma has created analytical restraints on 
the detection of these fetal point mutations as they are difficult to distinguish from 
the corresponding maternal wild type sequences (Chiu et al., 2009). 
Most issues that arise from conventional methods are related to the interference 
caused by the high maternal DNA background (Gibson, 2006). Many investigators 
have attempted different methods to suppress the maternal background for detection 
of fetal DNA polymorphisms (Li et al., 2004a, Li et al., 2004b, Li et al., 2005, 
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Galbiati et al., 2006，Galbiati et al., 2008). However, it would be ideal if one can 
develop an analytical technique that allows extraction of the fetal genetic 
information in spite of the coexisting maternal background. 
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3.4. AIMS OF THIS THESIS 
To improve qualitative and quantitative assessments of circulating fetal nucleic acids 
in maternal plasma, strategies must be developed to maximize the absolute amount 
and the relative proportion of fetal targets while minimizing interferences caused by 
the non-target maternal background. In this thesis, I shall illustrate how the major 
challenges associated with current maternal plasma analysis of fetal DNA and RNA 
can be resolved through innovative assay designs, refinements on established 
techniques and technological advancements. 
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SECTION II: MATERIALS AND METHODS 
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CHAPTER 4: QUANTITATIVE AND QUALITATIVE ANALYSIS OF NUCLEIC 
ACIDS 
4.1. SAMPLE COLLECTION AND PROCESSING 
4.1.1. Preparation of plasma and blood cells 
Peripheral blood samples were collected into EDTA-containing tubes. For plasma 
separation, the blood samples were first centrifuged at 1,600 g for 10 min at 4°C 
(Centrifuge 581 OR; Eppendorf，Hamburg, Germany). The plasma portion was 
carefully transferred to plain polypropylene tubes for a second round of 
centrifugation at 16,000 g for 10 min at 4 � C (Centrifuge 5415R; Eppendorf) to 
remove any residual blood cells (Chiu et al , 2001b). The acellular supematants were 
then transferred to fresh polypropylene tubes without disturbing the cell pellet. 
Plasma samples were stored at -20°C until DNA extraction. 
Upon removal of the plasma from the first centrifugation step, the buffy coat portion 
containing most of the white blood cells and platelets was recentrifuged at 2,500 g 
for 5 min. After removal of the residual plasma, blood cell samples were stored at 
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-20°C until DNA extraction. 
For RNA analysis, every 1.6 mL plasma harvested from the second centrifiigation 
step was mixed thoroughly with 2 mL TRIzol LS reagent (Invitrogen, Carlsbad, CA). 
The Trizol LS reagent is a solution of phenol and guanidine isothiocyanate with the 
capabilities of denaturing cell components and inactivating RNases, thus 
maintaining the RNA integrity in the samples. RNA samples were stored at -80°C 
until RNA extraction. 
4.1.2. Preparation of placental tissues 
Placental tissue samples were collected on site immediately after elective cesarean 
delivery. Placental tissues were collected within a three-centimeter diameter from 
the umbilical cord. After removal of the outermost maternal and fetal surfaces, tissue 
samples were first washed in water treated with diethyl-pyrocarbonate (DEPC) 
(Sigma-Aldrich, St. Louis, MO), and were incubated in polypropylene tubes 
containing KNAlater (Ambion Austin, Texas) at 4°C overnight for RNA stabilization. 
Tissue samples were stored at -80°C after removal of the KNAlater the next day. 
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4.2. NUCLEIC ACID EXTRACTION 
4.2.1. Extraction of total RNA 
4.2.1.1. Plasma samples 
Plasma RNA was extracted using the RNeasy Mini Kit (Qiagen) with a modified 
protocol that incorporates the use ofTRIzol LS reagent (Ng et al.，2002), which is an 
improvement to the single-step RNA extraction method developed previously 
(Chomczynski and Sacchi, 1987) and has been shown to recover higher amount of 
RNA than each standalone method (Wong et al , 2004). For total RNA extraction, 
3.6 mL TRIzol LS-plasma mixture (1.6 mL plasma plus 2mL TRIzol LS reagent) 
was first mixed with 0.4 mL chloroform, and was then centrifuged at 12,000 g for 15 
min at 4°C (Centrifuge 5415R; Eppendorf) for phase separation. After centrifugation, 
the mixture was separated into 3 phases with RNA in the aqueous phase, DNA in the 
organic phase, and proteins at the interphase. Total RNA in the aqueous layer was 
carefully transferred into fresh polypropylene tubes and then extracted using the 
RNeasy Mini Kit according to the manufacturer's protocol. First, one volume of 
70% ethanol was mixed with one volume of the aqueous layer by inversion to 
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provide appropriate column binding conditions. The mixture was then transferred 
into an RNeasy spin column (Qiagen) and was centrifuged at 9,300 g for 15 s. After 
the total RNA was adsorbed to the membrane, the column was then washed with 350 
|iL of Buffer RWl followed by two additional washes with 500 }iL of Buffer RPE. 
After washing, 30 \iL RNase-free water was used to elude the extracted RNA. 
To control genomic DNA contamination in the samples, the extracted RNA was 
subjected to DNase I digestion using Amplification Grade DNase I (Invitrogen). 3 
\iL lOX DNase I reaction buffer and 3 |iL DNase I were added to 30 |iL extracted 
RNA on ice. The mixture was then incubated at room temperature for 15 min. 
Finally, 3 i^L of 25 mM EDTA solution was added to the mixture followed by 
incubation at 65°C for 10 min for DNase I inactivation. The DNase I treated RNA 
samples were stored at -80°C until subsequent analysis. 
4.2.1,2. Placental tissue samples 
For total RNA extraction in placental tissues, each tissue sample was homogenized 
in 3 mL of TRIzol Reagent (Invitrogen) with a tissue homogenizer (Polytron, 
Norcross, GA). The homogenate was centrifuged at 12,000 g for 10 min at 4°C to 
46 
Materials and methods 
spin down the cell debris in the sample. The supernatant was then transferred to a 
new tube and incubated with 0.6 mL chloroform for 5 min at room temperature 
followed by centrifugation at 12,000 g for 15 min at 4°C. After phase separation, the 
aqueous phase was carefully transferred into fresh tubes and was precipitated with 
1.5 mL isopropanol for 10 min at room temperature followed by centrifugation at 
12,000 g for 10 min at 4°C. After removal of the supernatant, the RNA pellet was 
washed with 75% ethanol, air-dried, and dissolved in 30 \i\ RNase-free water. 
After extraction, the total RNA concentration for each sample was quantified using 
the NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) prior to DNase I treatment (Invitrogen). 
DNase I digestion was performed according to the manufacturer's protocol. 1 |ig of 
total RNA was mixed on ice with 2 |aL DNase I，2 \xL lOX DNase I reaction buffer, 
and RNase-free water to a total volume of 20 \iL. The mixture was then incubated at 
room temperature for 15 min. Finally, 2 |iL of 25 mM EDTA solution was added to 
the mixture followed by incubation at 65°C for 10 min for DNase I inactivation. The 
DNase I treated RNA samples were stored at -80°C until subsequent analysis. 
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4.2.2. Extraction of genomic DNA 
4.2.2.1. Plasma samples 
DNA from the plasma samples was extracted according to the blood and body fluid 
protocol of the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) or the 
QIAampDSP DNA Blood Mini Kit (Qiagen). 800 |liL of plasma was mixed with 80 
HL of Qiagen protease and 800 |iL buffer AL. The mixture was incubated at 56�C for 
10 min. After incubation, 800uL of absolute ethanol stored at 4 � C was added to the 
mixture for DNA precipitation. The mixture was transferred into a QIAamp Mini 
Spin Column or a QIAamp DSP Mini Spin Column stored at 4°C，and was 
centrifuged at 16,000 g for 1 min. The column was then washed with the wash 
buffers of AWl and AW2. After washing, 50 |xL of DNase/RNase-free water was 
used to elute the extracted DNA. The extracted DNA was stored at -20°C 
immediately until subsequent analysis. 
4.2.2.2. Blood cell samples 
48 
Materials and methods 
DNA from the blood cell samples was extracted according to the blood and body 
fluid protocol of the QIAamp DNA Blood Mini Kit (Qiagen). 400 [iL of blood cells 
was mixed with 80 i^L of Qiagen protease and 800 i^L buffer AL. The mixture was 
incubated at 56°C for 10 min. After incubation, 400uL of absolute ethanol stored at 
4°C was added to the mixture for DNA precipitation. The mixture was transferred 
into a QIAamp Mini Spin Column and centrifuged at 16,000 g for 1 min. The 
column was then washed with the wash buffers of AWl and AW2. After washing, 50 
|xL of DNase/RNase-free water was used elude the extracted DNA. The extracted 
DNA was stored at -20°C immediately until subsequent analysis. 
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4.3. CONVENTIONAL REAL-TIME PCR ANALYSIS OF NUCLEIC ACIDS 
4.3.1. Principles of real-time polymerase chain reaction 
qPCR is based on conventional polymerase chain reaction (PCR), where a forward 
primer and a reverse primer are need for the amplification of the target sequence. 
The key feature of qPCR is its ability to detect the amplified products in real time, 
which is made possible by the use of a nonspecific fluorescent dye that binds to any 
double-stranded DNA or a sequence-specific DNA probe that only binds to its 
complementary DNA target. In this thesis, all the qPCR assays used are TaqMan 
assays (Applied Biosystems). The TaqMan assay consists of a TaqMan probe, a 
single-stranded synthetic oligonucleotide, designed to hybridize to the target 
sequence to increase the specificity of the assay. The TaqMan probe is dually labeled 
with a fluorescent reporter dye at the 5' end and a quencher dye at the 3' end. When 
it is intact, the proximity of the quencher inhibits fluorescence emission by the 
reporter dye through energy transfer. The presence of the target sequence will induce 
hybridization of the probe to its complementary sequence. During the extension 
phase, the annealed probe is cleaved by the 5' nucleases activity of the DNA 
polymerase, separating the reporter and the quencher, thus increasing fluorescence 
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emission. The amount of fluorescence released is directly proportional to the number 
of amplicons replicated in each PGR cycle; it is detected and measured by the 
instrument as PGR products accumulated. Thus, the sequence of the probe provides 
additional specificity to the assay as only amplification of the intended sequence will 
result in fluorescence emission, while nonspecific amplification due to mispriming 
or primer dimers will not lead to such consequence. 
The development of minor groove binding (MGB) probes (Kumar et al., 1998) has 
greatly enhanced the efficiency and sensitivity of qPCR analysis (Kutyavin et al., 
2000, Afonina et al., 2002). By replacing the standard 3' quencher dye with a 
non-fluorescent quencher, the TaqMan MGB probes (Applied Biosystem) have 
higher melting temperatures that allow users to design shorter probes, which are 
more specific to their target sequences. 
All qPCR assays described in this thesis were performed on the ABI 7300 
Real-Time PGR System or the ABI 7900HT Fast Real-Time PGR System (Applied 
Biosystems). Reactions were performed in closed, optical tubes of Micro Amp® 
Optical 96-Well Reaction Plate (Applied Biosystems). 
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For data analysis, sequence detection system software vl.2.3 (Applied Biosystem) 
was used. Quantification of nucleic acids is achieved by comparing the Ct value of 
an unknown sample to a standard curve as described earlier in the thesis. 
4.3.2. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
In this thesis, one-step real-time quantitative reverse transcriptase-PCR (qRT-PCR) 
was used to measure the mRNA concentrations of placental transcripts in various 
samples. All qRT-PCR assays were designed to be intron spanning to avoid genomic 
DNA amplification. For absolute RNA quantification, calibration curves were 
prepared by serial dilutions of high performance liquid chromatography 
(HPLC)-purified single-stranded synthetic DNA oligonucleotides (Proligo) with 
concentrations ranging from 2.5 x 10^ copies to 2.5 copies per reaction. It has been 
demonstrated that single-stranded oligonucleotides can reliably generate calibration 
curves identical to those produced by T7-transcibed RNA (Bustin, 2000). 
qRT-PCR reaction was set up in a reaction volume of 25 |iL with components 
provided in the TaqMan EZ reverse transcriptase-polymerase chain reaction 
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(RT-PCR) Kit (Applied Biosystems) according to the manufacturer's instructions. 
The polymerase used was a recombinant Thermus thermophilus {xTth) DNA 
polymerase, which provided the dual functions of a reverse transcriptase and a 
polymerase (Myers and Gelfand, 1991). AmpErase uracil N-glycosylase (UNG) 
(Applied Biosystems) was used to degrade dU-containing carryover PGR products 
prior to the start of the RT-PCR process (Longo et al., 1990). In general, the reaction 
was initiated at 50°C for 2 min for UNG activation, followed by a reverse 
transcription step at 60°C for 30 min. After a 5 min denaturation at 95°C，45 cycles 
of PGR were carried out with denaturation at 94°C for 20 s and 1 min of annealing 
or extension at the optimized temperature for each assay. In each analysis, samples 
and calibration standards were run in duplicate; multiple wells of water blanks were 
also included as negative controls to monitor the level of contamination. 
4.3.3. Quantitative polymerase chain reaction (qPCR) 
While quantification of mRNA concentration relies on the use of qRT-PCR, 
measurement of DNA in samples was achieved by qPCR. qPCR and qRT-PCR 
essentially share the same principles with the exceptions that qPCR does not include 
a reverse transcription step and uses the AmpliTaq Gold DNA polymerase, which is 
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an enzyme derived from Thermus aquaticus {Taq). In addition, calibration curves 
used in qPCR were prepared by serial dilutions of human male genomic DNA 
extracted from blood cells with concentrations ranging between 0.78 and 10,000 GE 
per 5 mL. 
qPCR were set up in reaction volumes of 25|aL and 50 \xL using the TaqMan PCR 
Core Reagent Kit (Aplied Biosystems). In general, the reaction was initiated at 50°C 
for 2 min for UNG activation. After deactivation of UNG at 95°C for 10 min, 45 
cycles of PCR were carried out with denaturation at 95°C for 30 s and 1 min of 
annealing or extension at the optimized temperature for each assay. 
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4.4. DIGITAL REAL-TIME PCR ANALYSIS OF NUCLEIC ACIDS 
4A.1. Principles of digital PCR (dPCR) 
The concepts of digital PCR (dPCR) were first described by Vogelstein and Kinzler 
in 1999 (Vogelstein and Kinzler, 1999). It involves an initial step of sample dilution 
to dilute the extracted nucleic acids to concentrations predetermined by the users. 
Each diluted sample is then dispensed into the reaction wells of one or more of the 
96-well and 384-well optical plates. Digital analysis is achieved by separating 
nucleic acids into discrete units prior to PCR amplification and the concentrations of 
nucleic acids need to be diluted enough such that on average one or less template 
molecule is present in each PCR well. Using this approach, a large number of 
discrete amplification reactions will be carried out in one single PCR run. Single 
molecule detection can be made possible by the use a sequence specific fluorescent 
probe targeting the gene of interest. A well with a positive signal indicates the 
present of a target molecule. By counting the total number of positive wells, the 
absolute number of template molecules in the sample can be estimated without the 
need to draw reference from a calibrator. However, the positive signals are 
distributed following Poisson probabilities, meaning a single reaction well could 
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contain zero, one or more template molecules; therefore，quantification of the actual 
number of template molecules needs to be adjusted accordingly. 
According to the Poisson distribution, the expected proportion of wells with no 
template was given by e""*, where m is the average concentration of template 
molecules per well. For example, at an average concentration of one template 
molecule per well, the expected proportion of wells with no template molecule 
would be given by e'^ i.e., 0.37 (=37%). The remaining 63% of wells would contain 
one or more template molecules. Thus, the number of positive counts obtained by a 
dPCR analysis could be used to calculate the actual concentration of template 
molecules in the original sample in absolute quantity. 
4A.2. 384'reaction well dPCR 
In this thesis, dPCR was used for single molecule allelic discrimination in maternal 
plasma. In contrast to the non-digital qPCR assays, which used the TaqMan probes 
(Applied Biosystem); all the dPCR assays described in this thesis used the more 
sensitive and specific TaqMan MGB probes (Applied Biosystem) for allelic 
discrimination. dPCR reactions were carried out using MicroAmp® Optical 
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3 84-Well Reaction Plates (Applied Biosystems) analyzed by the ABI 7900HT Fast 
Real-Time PCR System (Applied Biosystems). Each dPCR reaction was set up in a 
reaction volume of 5 jiL with the TaqMan Universal PCR Master Mix (Applied 
Biosystems) according to the manufacturer's instructions. The reaction was initiated 
at 50°C for 2 min for UNG activation. After deactivation ofUNG at 95°C for 10 min, 
45 cycles of PCR were carried out with denaturation at 95°C for 30 s and 1 min of 
annealing/extension at 60°C. 
4.4.3. Microfluidics dPCR 
The BioMark Digital Array system (Fluidigm, South San Francisco, CA) is a high 
throughput platform for dPCR analysis. Through integrated fluidic circuits, a digital 
array employs a network of integrated channels, chambers and valves to 
automatically divide one sample or reagent mixture into many parts. On a 12.765 
Digital Array chip (Fluidigm), there are twelve panels, each of which is further 
partitioned into 765 chambers; allowing hundreds of PCR reactions of 6 nL to run 
simultaneously within each panel. In the BioMark Digital Array system，the work 
flow for dPCR analysis consists of the following steps: reaction setup, chip priming, 
sample loading, real-time PCR and data analysis. 
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For each panel, PGR reaction was set up in a reaction volume of 10 |xL, which 
contained 3.5 \iL of DNA sample, 0.5 |iL of Assay Loading Buffer (Fluidigm)，0.5 |xL 
of Sample Loading Buffer (Fluidigm), 5 |_iL of TaqMan Universal PGR Master Mix 
(Applied Biosystems), and the primer and probe mix. 
Chip priming and sample loading were performed on a NanoFlex 4-IFC Controller 
(Fluidigm). 300 |xL of 48.48 Control Line Fluid (Fluidigm) was injected into the left 
chamber of the 12.765 Digital Array chip. After 5 min of chip-priming, 10 i^L of 
PGR mix was added to each sample well; precautions were taken to ensure there 
were no air bubbles present in the sample wells by the end of the pipetting process. 
After 40 min of sample loading, the chip was transferred onto the BioMark 
Real-Time PGR System (Fluidigm) for thermal cycling and data collection. The 
thermal profile for the reaction is the following: initiation at 50°C for 2 min, 
incubation at 95�C for 10 min, followed by 60 cycles of 95°C for 15 s and 57�C for 1 
min. The recorded data was analyzed by the BioMark Digital Array software 
(Fluidigm). 
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4.5. MATRIX-ASSISTED LASER DESORPTION lONIZATION/TIME-OF-FLIGHT 
MASS SPECTROMETRY (MALDI-TOF MS) ANALYSIS OF NUCLEIC ACIDS 
4.5.1. Principles of MALDI-TOF MS 
Mass spectrometry (MS) is a highly precise analytical technique used to determine 
the composition of a sample of chemical compounds by characterizing its molecules 
according to their mass-to-charge ratio (Glish and Vachet, 2003). The principles of 
MS typically involves an initial step of sample vaporization followed by ionization 
of the components of the loaded sample through various methods; as the ions are 
accelerated through an electric field, the motions of the ions are detected by the 
instrument and sorted according to the mass-to-charge ratio of the particles. In this 
thesis, the platform used was the matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS). MALDI-TOF is a MS-based 
technology coupling the MALDI ionization technique and the time-of-flight 
spectrometer. In the process of MALDI-TOF MS, samples are first immobilized on a 
matrix, which protects the analyte biomolecules from being destroyed by the laser 
irradiation and facilitates ionization. Traveling through a vacuum tube within an 
electric field, the ionized molecules are separated by their molecular masses and 
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detected at the end of the flight path. Finally, a mass spectrum is generated for the 
identification of the analyte molecules (Tang et al., 1995，Ragoussis et al., 2006). 
4.5.2. DNA genotyping analysis by MassArray Homogenous MassExtend (hME) 
assay 
For genotype determination, DNA samples were processed by the Homogenous 
MassEXTEND (hME) assays on the SEQUENOM's MassARRAY system 
(Sequenom, San Diego, CA) prior to MALDI-TOF analysis. The hME assays were 
designed for the detection of single base changes in nucleotide sequences with high 
sensitivities. 
The principles of the hME reaction involve a first-round of PCR amplification. Each 
PCR reaction was set up in a reaction volume of 25 |iL containing Ix HotStart Taq 
PCR buffer with 1.5 M MgCb (Qiagen), an additional ImM MgCh (Qiagen) 50 M 
each ofdATP, dGTP, and dCTP, lOOM dUTP (Applied Biosystems), 200 nM each of 
the forward and reverse primers (Integrated DNA Technologies), and 0.1 U of 
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HotStar Taq Polymerase (Qiagen). The PCR reaction was initiated at 95�C for 7 min, 
followed by 45 cycles of 95°C for 40 s, 58°C for 1 min, and iTC for 1 min, and a 
final incubation at 70°C for 3 min. The PCR products were then treated with the 
shrimp alkaline phosphatase (SAP) reaction to remove any remaining dNTPs and 
prevent their incorporation in the subsequent primer extension step. 0.3 [iL of hME 
buffer and 3.06 \xL of water were added into the PCR product. The mixture was 
incubated at 37�C for 40 min followed by 85�C for 5 min. After SAP treatment, 4 \iL 
of base extension reaction mix was prepared by 771 nM extension primer 
(Integrated DNA technologies), 1.15 U of Thermosequenase (Sequenom), and 64 
|iM of dideoxynucleotide/deoxynucleotide (ddNTP/dNTP) mix (Sequenom) and was 
added to 10 |iL of the SAP-treated products. The reaction conditions were 94�C for 2 
min, followed by 94�C for 5 s，52�C for 5 s，and 72�C for 5 s for 75 cycles. The 
amplified products from the first-round of amplification would then serve as 
template molecules for the base-extension reaction, in which the extension primer 
would anneal adjacent to the polymorphic site of interest. By using the appropriate 
ddNTP/dNTP mix, one or a few more nucleotides will be extended depending on the 
sequence. The allele-specific extension products generated would have distinct 
masses that were readily resolvable by MALDI-TOF MS analysis. 12 mg of ion 
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exchange resin (Sequenom) and 24 i^L of water were mixed with the final base 
extension products at room temperature for 30 min for salt removal. Centrifiigation 
was performed at 361 g for 5 min to spin down the resin before 10 nL of the reaction 
solution was dispensed onto a 384-foraiat SpectroCHIP (Sequenom) by 
MassARRAY Nanodispenser (Sequenom). Mass spectrometry analysis of the 
dispensed analytes was performed by the MassARRAY Analyzer Compact Mass 
Spectrometer (Sequenom). Data analysis was performed by the MassARRAY Typer 
Software (Sequenom). 
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4.6. CLONING AND DNA SEQUENCING 
PCR products intended for subsequent analysis by sequencing were first TA-cloned 
into the pGEM T-Easy Vector (Promega) according to the manufacturer's 
instructions. For ligation, a vector-to-insert ratio of 1:3 was used. The amount of 
vector used was 25 ng in a 10 \iL reaction mixture. After an initial ligation step at 
16°C overnight, the product was transformed into Escherichia coli strain JM109 
High Efficiency Competent Cells by heat shock at 42°C for 50s. Cells were 
recovered in the Super Optimal broth with Catabolic repressor (SOC) medium 
(Invitrogen) for 1.5 hr at 37°C with shaking. The cells were then cultured on 
LB/ampicillin agar plates followed by overnight incubation at 37°C. After 
incubation, clones were picked randomly, dipped into 10 ^L of distilled water, and 
incubated at 95°C for 5 min. Vector primers T7 
(5'-TAATACGACTCACTATAGGG-3') and SP6 
(5'-ATTTAGGTGACACTATAGAA-3') (Proligo, Singapore) were used to amplify 
the cloned inserts. In a 12.5 |iL reaction mix, Ix Buffer II，2 mM MgCl】，200 |iM 
dNTP mix (Promega), 100 nM each of the forward and reverse primers (Proligo), 
and 1.25 U of AmpliTaq Gold were added with 1.5 |iL of the clone solution. The 
PCR reaction was initiated at 95°C for 10 min, followed by 30 cycles of 95�C for 40 
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s，60°C for 1 min, 72°C for 1 min, and a final incubation at 72°C for 7 min. 
Cycle sequencing was performed using the BigDye version 1.1 Kit (Applied 
Biosystems). In a 10 |liL reaction, 1 |IL BigDye, 2 PL buffer, and 250NM sequencing 
primer were mixed with 1 |liL of the clone PGR product. The thermoprofile was 25 
cycles of 96°C for 30 s，50°C for 15 s，and 60°C for 4 min. 
Unincorporated dye terminators in the cycle sequencing products were removed by 
the DyeEx 2.0 Spin Kit (Qiagen). After clean up, 10 fiL of each sequencing product 
was denatured with 10 |aL of HiDi formamide (Applied Biosystems) at 95°C for 3 
min. 
Samples were then analyzed by the Genetic Analyzer 3100 (Applied Biosystems). 
Sequencing data were acquired by the ABI PRISM® 3100 Genetic Analyzer Data 
Collection Software vl.0.1 and analyzed by the Sequencing Analysis software 3.7. 
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SECTION III: IMPROVEMENTS ON 
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CHAPTER 5: ENRICHMENT OF PLACENTA EXPRESSED mRNA MARKERS BY 
WHOLE TRANSCRIPTOME PREAMPLIFICATION 
5.1. INTRODUCTION 
Maternal plasma analysis of circulating fetal mRNA offers a means for noninvasive 
prenatal assessment that is applicable to all pregnancies regardless of the fetal 
gender. NIPD of pregnancy-associated disorders, such as PET (Ng et al.，2003a, 
Purwosunu et al., 2009) and preterm labor (Zhong et al., 2005b), have been made 
possible by quantitative analysis of circulating placental mRNA. NIPD of T21 has 
also been demonstrated by the RNA-SNP allelic ratio approach (Lo et al., 2007b). 
Together, these studies have revealed the clinical potential of circulating placental 
mRNA analysis for NIPD. 
The scarcity of placental mRNA in maternal plasma has created difficulties for the 
analysis of multiple transcripts. A typical RNA extraction from maternal plasma is 
only sufficient for the analysis of several assays. However, there are numerous 
potential targets in the transcriptome where one might like to survey in order to find 
the most suitable biomarker for diagnosis. In addition, it has been shown that 
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accurate and precise RNA-SNP allelic ratio determination requires a minimum 
number of the target mRNA molecules to be available for analysis (Lo et al., 2007b). 
The low abundance of some placental mRNA species may lead to false negative 
results. Therefore, there is a need to develop methods to increase the absolute 
amount of placental mRNA in maternal plasma. 
As mentioned before, one of the methods for RNA enrichment is by whole 
transcriptome amplification. Whole transcriptome amplification is essentially a 
preamplification technique developed to uniformly amplify the entire RNA 
transcriptome prior to gene specific analysis. With such technology, hundreds of 
products can potentially be generated for one to survey multiple target. 
The preamplification technology was first described in a study in 1992, in which a 
random mixture of 15-base oligonucleotides was used for primer-extension 
preamplificaton (PEP) of single-sperm DNA (Zhang et al., 1992). RNA 
preamplification can be achieved by various methods including the use of random 
primers, adapter ligation, and poly-A priming. Commercially available 
preamplification kits, for examples, the TaqMan PreAmp Master Mix Kit (Applied 
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Biosystems), the QuantiTect Whole Transcriptome Kit (Qiagen), and the Full 
Spectrum RNA Amplification Kit (System Biosciences), have also been developed 
so that such a technique can be performed in most laboratories. 
An ideal preamplification reaction should fulfill the following criteria: 1) 
maintaining the original and complete mRNA sequence, 2) being able to amplify 
degraded and fragmented RNA, 3) uniformly amplifying across the whole RNA 
transcriptome, 4) having no bias towards 3，or 5’ ends of transcripts, 5) maintaining 
the relative levels of each mRNA species, 6) requiring no purification steps, 7) being 
able to amplify samples of low RNA inputs, and finally 8) generating enough 
products for multiple transcript analysis. 
The purpose of this part of the thesis is to assess the potential of the preamplification 
technology as a reliable technique to amplify placental mRNA for noninvasive gene 
expression profiling from maternal plasma. 
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5.2. MATERIALS AND METHODS 
5.2.1. Study design 
The study comprised of three modules. The first module (module 1) focused on the 
comparison of mRNA expression profiles in placental tissues with and without the 
treatment of preamplification. The second module (module 2) investigated the effect 
of RNA input on the degree of enrichment. The third module (module 3) studied the 
feasibility of enrichment of placental mRNA in maternal plasma by 
preamplification. 
Module 1: 
mRNA expression profiling was performed in placental tissues with and without the 
treatment of preamplification. mRNA concentrations of four placenta expressed 
transcripts and one house-keeping gene were analyzed by the qPCR platform. 
Human placental lactogen (hPL), tissue factor pathway inhibitor 2 (TFPI2) and 
KiSS-1 metastasis suppressor (KISSl) were purposely selected because of their 
differences in ranking on the list of 50 most highly expressed placental transcripts 
identified by previous microarray analysis (Tsui et al., 2004). In addition, collagen, 
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type VI, alpha 1 (COL6A1) was also included in this study because of its 
intermediate expression level in the human placenta. The 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, a house-keeping gene 
that is expressed constitutively in nature, was chosen as a reference gene for the 
comparison of mRNA expression levels in placental tissues. 
Module 2: 
To understand the correlation between the RNA input and the degree of enrichment, 
I decided to stress the system by using the minimum amount of input RNA to initiate 
the preamplification reaction. I hypothesized that there existed a minimum threshold 
of RNA input for successful preamplification reactions. To test this hypothesis, 
placental tissue samples were serially diluted to mimic the conditions of maternal 
plasma. Samples with various concentrations were subsequently subjected to 
preamplification. Real-time PCR analysis was performed to quantify the hPL 
transcript, which was shown to have the highest expression level in the placenta 
among all the transcripts selected for this study (Tsui et al., 2004). 
Module 3: 
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To evaluate the feasibility of preamplifying plasma RNA, RNA samples were 
harvested from first trimester and third trimester maternal plasma. Maternal plasma 
samples were subjected to preamplification and qPCR analysis. hPL and KISSl were 
purposely chosen for gene specific analysis due to their moderately high expression 
levels in the placenta (Tsui et al., 2004). GAPDH was also included as a reference 
gene for comparison. 
5.2.2. Subjects and sample collection 
Peripheral blood samples were collected from healthy pregnant women in first 
trimester and third trimester pregnancies. All pregnant women were recruited with 
informed consent at the Department of Obstetrics and Gynaecology, Prince of Wales 
Hospital, Hong Kong. Plasma and placental tissue samples were obtained according 
to the procedures described in Chapter 4.1. The study was approved by the Joint 
CUHK-NTEC Clinical Research Ethics Committee. 
5.2.3. RNA extraction and sample dilution 
Module 1: 
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Total RNA was extracted from placental tissue with the protocol illustrated in 
Chapter 4.2.1.2. The total RNA concentration for each placental tissue sample was 
first measured by the NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop 
Technologies). After quantification, each sample was then diluted to the 
concentration of 1 ng/|iL. Both the undiluted and the 1 ng/|iL samples were 
subsequently subjected to preamplification and qPCR analysis. 
Module 2: 
The 1 ng/|iL samples prepared in module 1 were serially diluted. Samples with 
concentrations of 10 pg/|xL, 1 pg/|iL and 0.1 pg/|iL were subsequently subjected to 
preamplification and real-time PCR analysis. 
Module 3: 
Plasma RNA was extracted according to the protocol illustrated in Chapter 4.2.1.1. 
No dilution was performed on the plasma samples. Plasma RNA was subsequently 
subjected to preamplification and qPCR analysis. 
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5.2.4. Preamplification 
To ensure a fair comparison could be made, each extracted sample was thoroughly 
mixed and divided into two identical aliquots. Then, one of the two aliquots was 
subjected to the subsequent preamplification step, while the other one was not. 
Placental and plasma RNA samples were subjected to preamplification using 
components provided by the Full Spectrum'^^ Complete Transcriptome RNA 
Amplification Kit (System Biosciences) according to the manufacturer's protocol. 
The mechanism of the preamplification reaction was as follows:' first, the universal 
primers would bind to all regions of mRNA to initiate synthesis of the first strand 
cDNA. The remaining universal primer would then bind to the first strand cDNA to 
prime the second strand synthesis. Finally, PGR amplification would be performed 
on the double stranded cDNA template. 
For first strand cDNA synthesis, each reaction was set up in a total volume of 5 \iL 
including 2 \iL total RNA, 2 |xL Universal Primer Mixture, and 1 |xL RNase-free 
water. The mixture was incubated at 70°C for 4 min followed by 5 min incubation at 
25°C. After incubation, the solution was mixed with 5 \iL of the master mix prepared 
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by 2 |xL 5X Reverse Transcriptase Buffer, 1 |iL dNTP mix, 0.5 |iL Dithiothreitol, 0.5 
|iL Reverse Transcriptase, and 1 |xL RNase-free water. A second round of incubation 
was performed at 42°C for 50 min followed by 95°C for 5 min. The second strand 
cDNA synthesis was performed immediately by adding the following: 10 |xL lOX 
PCR Buffer, 2 |iL dNTP mix, 2 i^L Full Spectrum PCR Primer, 2 i^L PCR 
polymerase, and 74 \iL RNase-free water. The mixture was then cycled with the 
following thermal profile: 95°C for 4 min, 68°C for 5 min, 95°C for 25 s, 58°C for 1 
min, 68°C for 90 s，11 cycles of 95�C for 25 s and 68°C for 90 s, and 68°C for 2 min. 
The cDNA products were then stored in -20°C if not immediately used for analysis. 
5.2.5. qPCR analysis 
qPCR analysis was done on placental and plasma samples with and without 
preamplification. mRNA expression profiles of the original samples were 
determined by quantifying the target transcripts using qRT-PCR as described in 
Chapter 4.3.2. For samples that were treated with the preamplification step, the 
mRNA expression profiles were determined using qPCR as described in Chapter 
4.3.3. The reason being the mRNA in the treated samples had been converted into 
cDNA during the reverse transcription step involved in the preamplifcation reaction. 
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qRT-PCR assays for hPL (Ng et al., 2003b), TFPI2, KISSl (Tsui et al., 2004) and 
GAPDH (Ng et al., 2002) were previously described. The primer and probe 
concentrations as well as the annealing or extension temperature were optimized to 
give maximal fluorescent signal in each assay. The sequences of the primers 
(Proligo), probe (Applied Biosystems) and calibrators (Proligo) along with the 
annealing temperatures of the qRT-PCR reactions are listed in Table 5.1. Three 
microliters of RNA template was used in each reaction, with the exception of the 
C0L6A1 assay, in which 5 i^L of RNA was used. 
The calibration curve in the GAPDH qRT-PCR assay was prepared by a serial 
dilution of human control RNA (Applied Biosystems) with concentrations ranging 
from 5000 to 0.625 pg. According to the manufacturer, 1 pg of this control RNA 
contained approximately 100 copies of the GAPDH transcript (Ng et al., 2002). 
The absolute GAPDH mRNA concentration in each sample quantified by this 
control RNA was calculated using one of the following formulas: 
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C plasma = Q x 100 x (V 狐N ext) 
C placental tissue = Q ^ 1 0 0 / G input RNA 
where C piasma is the GAPDHmRNA concentration in plasma (copies/mL of plasma); 
Q is the RNA quantity determined by sequence detector (pg/jaL of RNA sample); V 
RNA is the total volume of RNA solution after the RNA extraction and DNase I 
treatment; V ext is the volume of plasma used for extraction; C placental tissue is the 
GAPDH mRNA concentration in placental tissue (copies/ng of total RNA); and C 
i叩utRNA is the concentration of the input total RNA (ng/^iL). 
For the quantification of cDNA in samples treated with preamplification, the same 
sets of primers, probe and calibrator used in the qRT-PCR assays were reused in the 
qPCR assays. The primer and probe concentrations as well as the annealing 
temperatures were also kept the same as the qRT-PCR assays (Table 5.2). 
Since the calibrator in the GAPDH qRT-PCR assay is produced by human control 
RNA, which cannot be used for DNA quantification due to the lack of a reverse 
transcript step in qPCR; a new calibrator was made for the GAPDH qPCR assay. 
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The calibrator of the GAPDH gene was generated by T/A cloning. PCR was 
performed on human pooled organ cDNA (Clontech, Mountain View, CA) to 
generate and amplify a single cDNA sequence containing the GAPDH gene using 
reagents provided in the Advantage cDNA polymerase Mix (Clontech). The 
sequences of the forward and reverse primers are 
5'-GAAGGTGAAGGTCGGAGT-3' and 5'-ACCCTGTTGCTGTAGCCAAA-3', 
respectively. The cDNA products were then cloned into the pGEM T-Easy Vector 
(Promega) according to the manufacturer's protocol. After an initial ligation step at 
4°C for 16 hr, the product was transformed into JM109 High Efficiency Competent 
Cells by heat shock. The cells were then cultured on LB/ampicillin agar plates 
followed by overnight incubation at 37�C. After incubation, plasmid DNA was 
isolated using the Wizard Plus Minipreps DNA Purification Kit (Promega), and was 
confirmed by direct sequencing using the BigDye Terminator v3.1 Kit (Applied 
Biosystems). A calibration curve was then prepared by serial dilution of the 
extracted plasmid DNA with concentrations ranging from 2.5 x 10^ copies to 2.5 
copies. 
The absolute GAPDH mRNA concentration in each sample quantified by this 
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calibrator was calculated using one of the following formulas: 
C plasma = Q X (V rna /V ext) 
c placental tissue ~ Q_ / C input RNA 
where C piasma is the GAPDHmKNA concentration in plasma (copies/mL of plasma); 
Q is the RNA quantity determined by sequence detector (copies/jiL of RNA sample); 
V RNA is the total volume of RNA solution after the RNA extraction and DNase I 
treatment; V ext is the volume of plasma used for extraction; C placental tissue is the 
GAPDH mRNA concentration in placental tissue (copies/ng of total RNA); and C 
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Table 5.2 Comparison of the qRT-PCR and qPCR assays for the hPL transcript. 
(A) One-step qRT-PCR reaction mixture (EZ rXth RNA PGR Reagent Kit; 
Applied Biosystems) 
Volume per reaction Final 
Components , •、 ^ 
(|jL) concentration 
5X TaqMan EZ Buffer 5 1X 
Mn(0Ac)2 (25 mM) 3 3 mM 
dATP (10 mM) 0.75 300 [jM 
dCTP (10 mM) 0.75 300 pM . 
dGTP (10 mM) 0.75 300 pM 
dUTP (20 mM) 0.75 300 |jM 
Forward primer (10 |jM) 1.125 450 nM 
Reverse primer (10 pM) 1.125 450 nM 
TaqMan Probe (5 pMf 0.75 150 nM 
AmpErase UNG (1 U/|jL)b 0.25 0.01 U/^L 
rTth DNA Polymerase (2.5 U/jjL) 1 0.1 U/^L 
Rnase-free water 6.75 -
RNA sample 3 -
Total ^ -
a Dual-labeled fluorescent probe containing a reporter at the 5' end (FAM, 6-carboxyfluorescein) and a quencher at 
the 3’ end (TAMRA, 6-carboxytetramethylrhodamine). 
b UNG, uracil-N-glycoslase 
Thermal profile of one-step qRT-PCR reaction 
Step Temperature Time 
UNG treatment 50°C 2 min 
Reverse transcription 60°C 30 min 
UNG deactivation 95°C 5 min 
Denaturation 94°C 20 s 
45 Cycles 
Annealing / Extension 56 C 1 min 
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Table 5.2 Comparison of the qRT-PCR and qPCR assays for the hPL transcript. 
(Continued) 
(B) Composition of qPCR reaction mixture (TaqMan® PCR Core Reagent Kit; 
Applied Biosystems) 
Components Volume per reaction (pL) Final concentration 
10X TaqMan Buffer A 2.5 1X 
MgCb (25 mM) 4 4 mM 
dATP (10mM) 0.5 200 |jM 
dCTP (10mM) 0.5 200 mM 
dGTP (10mM) 0.5 200 |jM 
dUTP (20mM) 0.5 200 pM 
Forward primer (10 jjM) 1.125 450 nM 
Reverse primer (10 mM) 1.125 450 nM 
TaqMan Probe (5 |jM)a 0.75 150 nM 
AmpErase UNG (1 U/[ i l f 0.25 0.01 U/pL li 
AmpliTaq Gold® (5 U/|jL) 0.125 0.025 U/pL Ij 
Deionized water 10.125 -
cDNA sample 3 -
^ -
a Dual-labeled fluorescent probe containing a reporter at the 5’ end (FAM, 6-carboxyfluorescein) and a quencher at 
ii 
ii 
the 3’ end (TAMRA, 6-carboxytetramethylrhodamine). 
b UNG, uracii-N-glycoslase 
Thermal profile of qPCR reaction 
Step Temperature Time 
UNG treatment 50°C 2 min 
UNG deactivation 95°C 5 min 
Denaturation 94。C 20 s 
45 Cycles 。 
Annealing / Extension 56 C 1 min 
82 
Improvements on maternal plasma analysis of circulating RNA 
5.3. RESULTS 
5.3.1. Comparison of mRNA expression profiles in placental tissues with and 
without preamplification 
To investigate whether or not uniform amplification could be achieved across the 
whole RNA transcriptome, qPCR results for the 5 target transcripts in 5 placental 
tissue samples with and without preamplification were compared at two different 
concentrations: undiluted and at 1 ng/\iL. Absolute copy numbers of all the target 
transcripts were calculated in the original samples to give an input copy number for 
each transcript. Similarly, absolute copy numbers of those transcripts were also 
calculated in the preamplified products to give an output copy number for each 
transcript. The input and output copy numbers of each transcript were then directly 
compared to determine the output/input ratio, which was derived by dividing the 
output copy number by the input copy number in absolute quantity. If a transcript 
was successfully preamplified, it would yield a output/input ratio that is greater than 
the value of 1. If a preamplification reaction had failed, the output/input ratio would 
fall below the value of 1. 
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5.3.1.1. Undiluted placental tissue RNA 
The qPCR results revealed that preamplification reactions were successful for all the 
target transcripts in the undiluted samples (Figure 5.1). Figure 5.2 demonstrates that 
the original mRNA expression profile of the undiluted samples was generally 
preserved after preamplification except for some low abundant transcripts. However, 
the relative differences in the concentrations of the target transcripts were magnified. 
The median input and output copies, and the median output/input ratio for each 
transcript among the 5 placental tissue RNA samples are summarized in Table 5.3. 
For the undiluted samples, the degree of amplification was the highest in hPL, 
followed by GAPDH, TFPI2, KISSl and C0L6A1 in descending order. 
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Figure 5.2 mRNA expression profiles in undiluted placental tissue RNA with 
and without preamplification. 
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Table 5.3 The effect of preamplification on the absolute copy numbers of 
mRNA markers in undiluted placental tissue samples. 
. . . . , , . . Median 
^ Median Median 
Gene ^ ^ ^ output/input 
input copies output copies 
ratio 
hPL 7.93E+08 8.18E+11 1031 
TFPI2 9.61 E+07 8.17E+09 85.0 
KISS1 2.63E+07 1.99E+08 11.7 
C0L6A1 2.02E+06 9.07E+06 4.5 
GAPDH 1.36E+06 1.50E+08 117.1 
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5.3.1.2. Diluted placental tissue RNA 
For the diluted placental RNA samples (1 ng/|^L), real-time PCR results revealed 
that preamplification reactions were successful for all the target transcripts with the 
exception of GAPDH (Figure 5.3). This suggests that enrichment could still be 
achieved even when the RNA inputs were lower than 5 ng as recommended by the 
manufacturer. Figure 5.4 demonstrates that the original mRNA expression profiles of 
the 1 ng/|j,L samples were preserved after preamplification. Similar to the data for 
the undiluted samples, the degree of amplification was also different for each 
transcript in the 1 ng/|iL samples. The median input and output copies, and the 
median output/input ratio for each transcript are summarized in Table 5.4. The 
degree of enrichment was the highest in hPL, followed by TFPI2, C0L6A1, KISSl 
and GAPDH in descending order. 
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Figure 5.4 mRNA expression profiles in diluted placental tissue samples (1 
ng/|iL) with and without preamplification. 
90 
Improvements on maternal plasma analysis of circulating RNA 
Table 5.4 The effect of preamplification on the absolute copy numbers of 
mRNA markers in diluted 1 ng/|iL placental tissue samples. 
Median 
Median Median , , 
Gene output/input 
input copies output copies 
hPL 1.98E+07 1.94E+09 122 
TFPI2 2.19E+06 1.98E+07 10.1 
KISS1 5.38E+05 1.23E+06 1.6 
C0L6A1 4.61 E+04 2.72E+05 5.3 
GAPDH 3.20E+04 1.24E+02 0.0 
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5.3.2. The effect of RNA input on the degree of amplification 
To study the effect of RNA input on the degree of enrichment, real-time PCR results 
from 5 placental tissue samples with and without preamplification were compared 
for the hPL transcript at five different concentrations: undiluted, Ing/^iL, 10 pg/|xL, 
1 pg/jiL and 0.1 pg/|iL. As described in module 1，the input and output, copy 
numbers and the output/input ratio were calculated at each concentration and are 
listed in Table 5.5. The reaction was deemed successful when the output/input ratio 
was greater than 1. A reaction was deemed as having failed when the output/input 
ratio fell below the value of 1. The minimum amount of RNA input was then 
determined by the lowest concentration that had led to successful preamplifcation 
reactions in all 5 placental tissue samples. 
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Table 5.5 The effect of preamplification on the absolute copy numbers of hPL 
mRNA in serially-diluted placental tissue samples. 
, , , , .. Median 
_ Median Median . ^ 
Concentration output/input 
input copies output copies 
ratio 
Undiluted 7.93E+08 8.18E+11 1031 
1 ng/pL 1.98E+07 1.94E+09 122 
lOpg/pL 74100 623000 10.4 
1 pg/|jL 18600 5607 0.3 
0.1 pg/|jL 558 0 0.0 
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5.3.2.1. Correlation between RNA input and RNA output 
qRT-PCR results revealed the median input copies for hPL were 74100 in the 10 
pg/|jL samples, 18600 in the 1 pg/jxL samples and 558 in the 0.1 pg/|xL samples. The 
median output copies for hPL were 623000 in the 10pg/|aL samples, 5607 in the 
Ipg/jiL samples and 0 in the 0.1pg/|iL samples. Combining these data with those for 
the undiluted and lng/|iL samples in module I，RNA output was shown to be 
positively correlated to the RNA input (Figure 5.5, Spearman correlation analysis, r^  
=0.973，p<0.05) for the hPL transcript. 
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Figure 5.5 Correlation between RNA input and RNA output in serially diluted 
placental tissue samples. 
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5.3.2.2. Correlation between RNA input and output/input ratio 
A median of 10.4-fold elevation was observed for the hPL transcript in the 10pg/|iL 
samples after preamplification; however, the median output/input ratios for the 
lpg/|aL and 0.1pg/|iL samples were 0.3 and 0, respectively. Combining these data 
with those previously presented for the undiluted and Ing/jxL samples, RNA input 
was shown to be positively correlated to the output/input ratio (Figure 5.6, Spearman 
correlation analysis, r^  = 0.936, p<0.05) for the hPL transcript. These results 
indicated that preamplification was successful in significantly diluted placental 
tissues samples, strengthening its possible application to plasma RNA. However, the 
data for samples with concentrations of Ipg/jiL and O.lpg/jiL suggested 
preamplification would eventually fail if the input RNA became too low. 
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Figure 5.6 Correlation between RNA input and output/input ratio in serially 
diluted placental tissue samples. 
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5.3.3. Preamplification of maternal plasma RNA 
To further explore the possibility of amplifying plasma RNA, qPCR results from 2 
third trimester and 2 first trimester maternal plasma samples with and without 
preamplification were compared for the GAPDH, hPL and KISSl transcripts. 
5.3.3.1. Concentrations of placenta expressed mRNA in third trimester maternal 
plasma 
In the third trimester plasma samples, the average input copies were 3061 for 
GAPDH, 5413 for hPL and 197 for KISSL The average output copies were 765000 
for GAPDH, 735000 for hPL and 0 for KISSl. The average output/input ratios for 
GAPDH, hPL, and KISSl were 252, 125 and 0，respectively. These results indicated 
that preamplification reactions were successful in the third trimester maternal 
plasma samples for the enrichment of GAPDH and hPL mRNA, but not for KISSl 
mRNA (Figure 5.7). 
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Figure 5.7 Concentrations of mRNA markers in third trimester maternal plasma 
samples with and without preamplification. Plots of (A) hPL (B) KISSl (C) GAPDH 
mRNA. 
99 
Improvements on maternal plasma analysis of circulating DNA 
5.3.3.2. Concentrations of placenta expressed mRNA in first trimester maternal 
plasma 
In the first trimester plasma samples, the average input copies were 1180 for 
GAPDH, 380 for hPL and 39 for KISSl. The average output copies were 42000 for 
GAPDH, 48000 for hPL and 0 for KISSl. The average output/input ratio for 
GAPDH, hPL, and KISSl were 34, 128 and 0 respectively. Similar to the third 
trimester maternal plasma samples, successful preamplifications were observed in 
the first trimester maternal plasma samples for GAPDH and hPL mRNA transcripts, 
but not for KISSl mRNA (Figure 5.8). 
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Figure 5.8 Concentrations of mRNA markers in first trimester maternal plasma 
samples with and without preamplification. Plots of (A) hPL (B) KISSl (C) GAPDH 
mRNA. 
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5.4. DISCUSSION 
qRT-PCR is a widely used technique for the quantification of mRNA concentrations 
in gene expression analysis. Although the input amount of RNA for qRT-PCR 
analysis can be as low as 0.1 to 1 ng, it is often difficult to obtain sufficient starting 
materials when a panel of transcripts is being examined. This problem is particularly 
highlighted in field of prenatal diagnosis, as placenta expressed mRNA transcripts 
are only present in limited quantities in maternal plasma depending on the 
expression level of the corresponding gene in the placenta. As a result, it is very 
difficult to harvest enough placental RNA for mRNA expression profiling in 
maternal plasma. For these reasons, there is a need to have a reliable and robust 
approach to increase the absolute quantities of placental RNA abundance in maternal 
plasma prior to expression analysis. 
In this part of the thesis, the performance of the preamplification technology was 
evaluated as a possible means to increase placenta expressed mRNA abundance for 
prenatal diagnosis. The preamplification technology could potentially provide an 
inexpensive method to amplify mRNA species in maternal plasma so that numerous 
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tests can be done on a single tube of maternal blood. However, for reliable and 
accurate quantitative maternal plasma analysis, it is important that the 
preamplification reaction offers not only uniform amplification across the entire 
transcript but also maintenance of relative transcription levels for each species of 
RNA in the starting mRNA population. Finally, the feasibility of plasma RNA 
preamplification relies on both the minimum input amount of starting material for 
the reaction and its ability of amplifying partially degraded RNA. 
In module 1，it was demonstrated that preamplification of placental RNA was 
successful even when the total RNA concentration of the samples was as low as 1 
ng/|aL. By ranking the relative abundances of all target transcripts in samples with 
and without the treatment of preamplification, the original mRNA expression profile 
was shown to be generally preserved except for low abundant transcripts. However, 
the output/input ratio calculations suggested that uniform amplification was not 
achieved as the preamplification reaction had magnified the differences of the 
relative concentrations among transcripts. 
In module 2, it was demonstrated that preamplification of placental RNA was 
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successful in concentrations lower than Ing/pl. In addition, RNA input was shown 
to be positively and significantly correlated to both the RNA output and the 
output/input ratio. However, preamplification reactions failed in samples containing 
less than 10 pg/|il of total RNA, suggesting that there existed a minimum threshold 
of RNA input for successful preamplification reaction. 
In module 3，preamplification of placenta expressed mRNA was shown to be 
feasible in both third and first trimester maternal plasma samples. While 
preamplification reactions were shown to be successful for the highly expressed 
transcripts, preamplification was unsuccessful for transcripts of low abundance. 
These findings could be explained by insufficient RNA input or the 
partially-degraded nature of the circulating fetal RNA in maternal plasma. Further 
investigation is needed to improve the performance of preamplification for 
circulating placental RNA analysis. 
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SECTION IV: IMPROVEMENTS ON 
MATERNAL PLASMA ANALYSIS OF 
CIRCULATING DNA 
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CHAPTER 6: ACCURATE GENE DOSAGE ANALYSIS BY MULTIPLEX qPCR 
6.1. INTRODUCTION 
Gene dosage comparison is a common technique used for the study of chromosomal 
abnormalities in both cancer genetics and prenatal diagnosis. In the cancer setting, 
gene dosage comparison is used for the investigation of chromosomal instability, 
such as chromosome gains and losses and loss of heterozygosity (LOH) (Zhou et al., 
2001, Chang et al., 2002, Zhou et al., 2002). Chromosome gains and losses are 
caused by an addition or a deletion of an entire chromosome in the genome, and 
have been described in various cancers including chronic lymphocytic leukemia 
(Robert et al., 1982), acute myeloid leukemia (Pedersenbjergaard and Rowley, 1994) 
and high-grade gliomas (Balesaria et al., 1999). LOH of tumor suppressor genes can 
be caused by a simple deletion of the normal allele, and has been shown to cause 
cells to become predisposed to the development of tumors (Buetow et al., 1989, 
Huang et al., 1992). In the prenatal setting, chromosomal aneuplodies, such as T21 
(Down Syndrome)，trisomy 18 (Edwards Syndrome), and trisomy 13 (Patau 
Syndrome), are caused by an additional chromosome present in the fetal genome. In 
addition, minor chromosomal abnormalities, for example, a Robertsonian 
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translocation, in which the long arm of chromosome 21 is joined with the long arm 
of another chromosome, is another cause for fetal Down Syndrome (Petersen et al, 
1991). In all of the above situations, assessment of allelic imbalances in the genome 
through gene dosage comparison may be useful for the diagnosis of those 
conditions. 
Gene dosage comparison typically measures quantitative differences between a 
disease locus and a non-affected locus. It requires accurate and precise 
quantification of genes on different loci or chromosomes. However, its application is 
not only limited to the detection of chromosomal aneuplodies (Lo et al., 2007a). The 
measurement of fractional fetal DNA concentration in maternal plasma also involves 
the same concept. The fractional concentration of cell-free fetal DNA in maternal 
plasma is calculated by the ratio of the absolute concentration of cell-free fetal DNA 
to the absolute concentration of total (maternal and fetal) cell-free DNA (Lo et al, 
1998b). Thus, the determination of fractional fetal DNA concentration relies on the 
gene dosage comparison of a fetal specific gene and a reference gene that is present 
in both the fetal and the maternal genomes. 
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In 1990s，when qPCR was commercially available for the first time, with the use of 
this technology, Lo et al. showed that the fractional fetal DNA concentration was 
0.39% - 11.9% (mean 3.4%) in early pregnancies, and 2.33%-11.4% (mean 6.2%) in 
late pregnancies (Lo et al., 1998b). However, it was later revealed that the fractional 
fetal DNA concentration in maternal plasma was higher than expected. In 2007, 
using dPCR technology, Lim et al demonstrated that the median fractional fetal 
DNA concentrations were 9.7%, 9.0% and 20.4% for normal pregnancies in the first, 
second, and third trimesters, respectively (Lun et al., 2008a). These findings have 
suggested that the median fractional concentration of circulating fetal DNA might be 
2-fold higher than previously recognized. This discrepancy can be explained by the 
inaccuracy of the conventional qPCR platform as suggested by Lun et al. However, 
the real question is, other than dPCR, are there other analytical facts that would 
allow accurate gene dosage assessment even with conventional qPCR? Or is there 
still room for improvement in the performance of conventional qPCR? The problems 
with conventional qPCR analysis include: 1) differences in amplification efficiencies 
among assays，2) variations caused by different assay formulations, and 3) the need 
for calibration standards for template quantification. In this part of the thesis, I 
investigated analytical factors that may improve the accuracy of the conventional 
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6.2. MATERIALS AND METHODS 
6.2.1. Study design 
To investigate analytical factors that may influence the accuracy of conventional 
qPCR for gene dosage comparison, a simple system was used as a model for 
ii 
investigation. In this model, gene dosage analysis was done on different types of 
samples by quantifying a Y-chromosomal locus against a reference chromosomal 
locus with a variety of qPCR assays. The study focused on the assessment of 
conventional qPCR in three modules. The first module (module 1) studied the 
influence of using the same and different sets of primers for amplifying different 
chromosomal loci. The second module (module 2) investigated effects of using 
monoplex and multiplex qPCR formulations. The third module (module 3) evaluated 
the effects of incorporating calibration curves for template quantification. 
Module 1: 
To study the effects of the primer sets, two different strategies were adopted in the 
assay design. The first strategy was to utilize two different primer sets to target two 
different loci, namely the 137-base pairs (bp) amplicon of the HBB gene on 
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chromosome 11 and the 101-bp amplicon of the sex-determining region Y{SRY) on 
chromosome Y. The second strategy was to design an identical set of primers to 
coamplify two 87-bp amplicons of Zinc Finger Protein sequences on chromosomes 
X and Y (ZFX and ZFY) and use chromosome-specific probes to distinguish them. I 
hypothesized that using the same set of primers for coamplification would reduce 
bias contributed by differences in the binding efficiencies of the two primer sets. 
Conventional qPCR was performed using these two strategies to determine the 
optimal assay design for qPCR-based analysis. 
Module 2: 
To investigate the effects of assay formulation, monoplex and multiplex assays were 
developed for both the HBB/SRY and ZFX/ZFY systems to determine the optimal 
formulation for conventional qPCR analysis. I hypothesized that combining two 
assays in a multiplex formulation would introduce less assay variation than the 
monoplex assays. In addition, the performances of different commercial real-time 
PCR kits were also compared in this module. 
Module 3: 
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Quantitative analysis using conventional qPCR typically requires the use of 
calibration curves. Due to the difference in amplification efficiencies between the 
samples and the calibrators, the gene dosages determined by qPCR may deviate 
from the true values in the starting materials. Furthermore, calibration curves may 
vary between laboratories and between matches of standards, thus 
I 
calibration-independent dPCR is believed to be intrinsically more accurate and 
reproducible in determining gene dosages than conventional qPCR (Lun et al., 
2008a). To evaluate the effects of incorporating calibration curves in conventional 
qPCR，a digital ZFX/ZFY assay was developed for the study. qPCR was performed 
in both a digital and non-digital manner to compare the accuracies of both systems. 
6.2.2. Subjects and sample collection 
Peripheral blood samples were collected from 10 healthy adult males with informed 
consent at the Department of Chemical Pathology, Prince of Wales Hospital, Hong 
Kong. 
Peripheral blood samples were collected from 10 healthy pregnant women in third 
trimester pregnancies with informed consent at the Department of Obstetrics and 
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Gynaecology, Prince of Wales Hospital, Hong Kong. 
Plasma and blood cells samples were obtained according to the procedures described 
in Chapter 4.1. The study was approved by the Joint CUHK-NTEC Clinical 
Research Ethics Committee. 
6.2.3. DNA extraction and sample dilution 
Genomic DNA was extracted from adult male blood cell samples with the protocol 
described in Chapter 4.2.2.2. For adult male and maternal plasma samples, DNA 
was extracted according to the protocol described in Chapter 4.2.1.2. The genomic 
DNA concentration for each adult male blood cell sample was measured by the 
NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies). 
6.2.4. qPCR analysis 
qPCR analysis was done on adult male blood cells, adult male plasma, and maternal 
plasma samples using different commercial qPCR kits. Genomic DNA extracted 
from blood cell s哗pies was diluted to 5 ng/|iL prior to analysis, while plasma DNA 
113 
Improvements on maternal plasma analysis of circulating DNA 
was subjected to qPCR without dilution. The sequences of the primers and probes 
are listed in Table 6.1. Calibration curves for template quantification were prepared 
by serial dilutions of human male genomic DNA as described in Chapter 4.3.3. 
6.2.4.1. Monoplex assays 
J 
Monoplex qPCR assays were developed for both the HBB/SRY and ZFX/ZFY 
systems. The monoplex HBB/SRY assay was set up using the TaqMan PGR Core 
Reagent Kit (Applied Biosystems) following the manufacturer's instruction (Table 
6.2). The monoplex ZFX/ZFY assay was set up using the 2X TaqMan Universal PGR 
Master Mix Kit (Applied Biosystems) according to the manufacturer's protocol 
(Table 6.3). 
6.2.4.2. Multiplex assays 
Multiplex qPCR assays were also developed for both the HBB/SRY and ZFX/ZFY 
systems. Both the multiplex HBB/SRY and the ZFX/ZFY SLSSoys were set up using the 
QuantiTect Multiplex PGR kit (Qiagen) following the manufacturer's instructions 
(Table 6.4 and 6.5A). However, an additional multiplex assay was developed for the 
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ZFX/ZFY system using a modified protocol of the TaqMan Universal PGR Master 
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Table 6.2 Monoplex qPCR assays for quantification of HBB and SRYD]^A. 
(A) Composition of qPCR reaction mixture (TaqMan® PGR Core Reagent Kit; 
Applied Biosystems) 
Components Volume per reaction (|jL) Final concentration 
10X TaqMan Buffer A 5 1X 
MgClz (25 mM) 8 4 mM 
dATP (10mM) 1 200 |jM 
dCTP (10mM) 1 200 pM 
dGTP(IOmM) 1 200 |JM 
dUTP (20mM) 1 200 |JM 
Forward primer (10 _ 1.5 300 nM 
Reverse primer (10 _ 1.5 300 nM 
TaqMan Probe (2.5 mM)" 2 100 nM 
AmpErase UNG (1 U/pLf 0.5 0.01 U/jjL 
AmpliTaq Gold® (5 U/|JL) 0.25 0.025 U/|JL 
Deionized water 22.25 -
DNA sample 5 -
^ -
a Dual-labeled fluorescent probe containing a reporter at the 5' end (FAM, 6-carboxyfluorescein)/(VIC, 
2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein) and a quencher at the 3’ end (TAMRA, 
6-carboxytetramethylrhodamine). 
b UNG, uracil-N-glycoslase 
(B) Thermal profile of qPCR reaction 
Step Temperature Time 
UNG treatment 50°C 2 min 
UNG deactivation 95°C 10 min 
Denaturation 95°C 15 s 
45 Cycles 
Annealing / Extension 60°C 1 min 
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Table 6.3 Monoplex qPCR assays for quantification of ZFXand ZFY DNA. 
(A) Composition of qPCR reaction mixture (2X TaqMan Universal PCR Master 
Mix Kit; Applied Biosystems) 
ZFX 
Components Volume per reaction (|JL) Final concentration 
2X TaqMan Universal PCR Master Mix^ 25 1X 
Forward primer (10 (jM) 1.5 300 nM 
Reverse primer (10 pM) 1.5 300 nM 
ZFX Probe (10 mM)" 0.5 100 nM 
Deionized water 16.5 -
cDNA sample 5 -
45 -
ZFY 
Components Volume per reaction (|JL) Final concentration 
2X TaqMan Universal PCR Master Mix^ 25 1X 
Forward primer (10 mM) 1.5 300 nM 
Reverse primer (10 |JM) 1.5 300 nM 
ZFY Probe (10 pM)b 2 400 nM 
Deionized water 15 -
cDNA sample 5 -
45 -
a with uracil-N-glycoslase (UNG) 
b Dual-labeled fluorescent probe containing a reporter at the 5' end (FAM, 6-carboxyfluorescein)/(VIC, 
2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfIuorescein) and a quencher at the 3' end (MGB NFQ, minor-groove 
binding non-fluorogenic quencher). 
(B) Thermal profile of qPCR reaction 
step Temperature Time 
UNG treatment 50°C 2 min 
UNG deactivation 95°C 10 min 
Denaturation 95。C 15 s 
45 Cycles 
Annealing / Extension 57。C 1 min 
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Table 6.4 Multiplex qPCR assay for quantification of HBB and SRY DNA. 
(A) Composition of qPCR reaction mixture (2X TaqMan Universal PGR Master 
Mix Kit; Applied Biosystems) 
Volume per Final 
Components i . , " … 
reaction ⑴L) concentration 
2X QuantiTect Multiplex PGR Master Mix 25 1X 
HBB Forward primer (1 OmM) 2 400 pM 
HBB Reverse primer (10mM) 2 400 jjM 
HBB Probe (2.5 |jM)a 4 200 i^M 
SRY Forward primer (1 OmM) 2 400 ^M 
SRY Reverse primer (10mM) 2 400 |jM 
SRY Probe (2.5 ^M)" 4 200 ^ M 
AmpErase UNG (1 U/jjL) 0.5 0.01 U/PL 
Deionized water 3.5 -
DNA sample 5 -
50 -
a Dual-labeled fluorescent probe containing a reporter at the 5' end (VIC, 
2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein) and a quencher at the 3' end (TAMRA, 
6-carboxytetramethylrhodamine). 
b Dual-labeled fluorescent probe containing a reporter at the 5’ end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3’ end (TAMRA, 6-carboxytetramethylrhodamine). 
(B) Thermal profile of qPCR reaction 
Step Temperature Time 
UNG treatment 50°C 2 min 
UNG deactivation 95。C 15 min 
Denaturation 94°C 1 min 
45 Cycles 
Annealing I Extension 60°C 1 min 
119 
Improvements on maternal plasma analysis of circulating DNA 
Table 6.5 Multiplex qPCR assay for quantification of ZFX and ZFY DNA. 
(A) Composition ofqPCR reaction mixture (QuantiTect Multiplex PCR kit; 
Qiagen) 
Volume per Final 
Components reaction (|JL) concentration 
2X QuantiTect Multiplex PCR Master Mix 25 1X 
Forward primer (1 OmM) 4 800 pM 
Reverse primer (1 OmM) 4 800 jjM 
ZFX Probe (10 nMf 1 200 pM • 
ZFY Probe (10 |jMf 1 200 |JM 
AmpErase UNG (1 U/ML) 0.5 0.01 U/PL 
Deionised water 9.5 -
DNA sample 5 -
50 -
a Dual-labeled fluorescent probe containing a reporter at the 5' end (VIC, 
2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein) and a quencher at the 3’ end (MGB NFQ, minor-groove 
binding non-fluorogenic quencher). 
b Dual-labeled fluorescent probe containing a reporter at the 5' end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3’ end (MGB NFQ, minor-groove binding non-fluorogenic quencher). 
Thermal profile of qPCR reaction 
Step Temperature Time 
UNG treatment 50°C 2 min 
UNG deactivation 95°C 15 min 
Denaturation _ ^ , 94°C 1 min 
45 Cycles „ 
Annealing / Extension 6 0 ^ 1 min 
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Table 6.5 Multiplex qPCR assay for quantification of ZFXand ZFYDNA. 
(Continued) 
(B) Composition ofqPCR reaction mixture (2X TaqMan Universal PCR Master 
Mix Kit; Applied Biosystems) 
Volume per Final 
Components ，，、 reaction (pL) concentration 
2X TaqMan Universal PCR Master Mix^  25 1X 
Forward primer (10 pM) 3 600 nM 
Reverse primer (10 pM) 3 600 nM 
ZFX Probe (10 ijM)b 0.5 100 nM 
ZFY Probe (10 |jMf 0.5 100 nM 
Deionised water 13 -
cDNA sample 5 -
45 -
a with uracil-N-glycoslase (UNG) 
b Dual-labeled fluorescent probe containing a reporter at the 5’ end (VIC, 
2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein) and a quencher at the 3' end (MGB NFQ, minor-groove 
binding non-fluorogenic quencher). 
c Dual-labeled fluorescent probe containing a reporter at the 5’ end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3’ end (MGB NFQ, minor-groove binding non-fluorogenic quencher). 
Thermal profile of qPCR reaction 
Step Temperature Time 
UNG treatment 50°C 2 min 
UNG deactivation 95°C 10 min 
Denaturation 95。C 15s 
45 Cycles „ 
Annealing / Extension 57°C 1 min 
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6.2.5. Microfluidics dPCR assay 
dPCR assay for the ZFX/ZFY system was previously described (Lun et al , 2008a). 
The concentrations of the primers and probes were: 900 nM of each of the forward 
and reverse primers, 125 nM of the ZFX probe, and 500 nM of the ZFY probe. 
Microfluids dPCR reactions were set up using components provided in the 2X 
TaqMan Universal PGR Master Mix Kit (Applied Biosystems) on the BioMark 
Digital Arrays (Fluidigm) analyzed by the BioMark Real-Time PGR system 
(Fluidigm) according to the protocols described in Chapter 4.4.3. For the ZFY/X 
assay, the detection threshold was set at FAM = 0.02，VIC = 0.2, and quality 
threshold at 0.3. 
Genomic DNA from adult male blood cell samples was diluted to 1 ng/|iL for dPCR 
analysis, while DNA from maternal plasma samples was directly added to the 
reaction mixtures without dilution. 
6.2.6. Gene Dosage Comparison 
By quantifying a Y-chromosomal locus against a reference chromosomal locus, gene 
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dosage comparisons were performed in adult male blood cells and plasma samples 
and in maternal plasma samples. 
6.2.6.1. In adult male samples 
In an adult male, a single copy of chromosome X and a single copy of chromosome 
Y are present in the genome. Theoretically, the number of ZFX molecules in an adult 
sample should equal to the number of ZFY molecules. Therefore, for the ZFX/ZFY 
assays, the ratio of ZFY.ZFX should give an expected value of 1 in adult male blood 
cells and plasma samples. 
Similarly, in an adult male, one GE of chromosome 11 and one GE of chromosome 
Y are present in the genome. Theoretically, the number of HBB GE in an adult 
sample should equal to the number of SRY GE. Therefore, for the HBB/SRY assays, 
the ratio of SRY:HBB should give an expected value of 1 in adult male blood cells 
and plasma samples. 
6.2.6.2. In maternal plasma samples 
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For a woman pregnant with a male fetus, the fetal genome contains a copy each of 
chromosome X and chromosome Y, while the maternal genome contains 2 copies of 
chromosome X and no chromosome Y. Therefore, for the ZFX/ZFY assays, the 
proportion of fetal DNA in a maternal plasma sample (i.e. the fractional fetal DNA 
concentration) is calculated by: (2 x ZFY)/(ZFY + ZFX) x 100%. 
Similarly, each male fetal cell contains one GE each of chromosome 11 and 
chromosome Y, while each background maternal cell only contains one GE of 
chromosome 11 but no chromosome Y. Thus, for the HBB/SRY assays, the fractional 
fetal DNA concentration was given by: (SRY GE)/(HBB GE) x 100%. 
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6.3. RESULTS 
For adult males, quantitative bias was determined for each tested method by 
comparing the observed ratio to the expected value of 1. For the determination of 
fractional fetal DNA concentrations, the result given by each tested method was 
compared against each other. 
6.3.1. The influence of using the same and different sets of primers for amplifying 
different chromosomal loci 
In this part of the study, the relative gene dosages determined by the ZFX/ZFY and 
HBB/SRY systems were compared. In adult male blood cell sample, the median 
(interquartile range) relative gene dosages determined by the ZFX/ZFY and 
HBB/SRY systems were 0.96 (0.88-0.99) and 1.15 (1.07-1.20), respectively. Gene 
dosages quantified by the ZFX/ZFY assay gave ratio that was significantly closer to 
the expected value of 1 than that determined by the HBB/SRY assay (Figure 6.1). 
In adult male plasma samples, the median (interquartile range) relative gene dosages 
determined by the ZFX/ZFY and HBB/SRY systems were 0.74 (0.68-0.85) and 0.74 
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(0.66-0.88)，respectively. Deviated from the expected value of 1，the relative gene 
dosages in the adult male plasma samples were underestimated by both systems 
(Figure 6.2). 
In maternal plasma samples, the median (interquartile range) fractional fetal DNA 
concentration determined by the ZFX/ZFY and HBB/SRY systems were 20.8% 
(16.4%-28.4%) and 9.3% (8.7%-13.5%), respectively. The fractional fetal DNA 
concentration determined by the ZFX/ZFY system was significantly higher than that 
determined by the HBB/SRY system (Figure 6.3). 
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Figure 6.1 Comparison of the relative gene dosages determined by the ZFX/ZFY 
and HBB/SRY systems in adult male blood cell DNA samples. 
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Figure 6.2 Comparison of the relative gene dosages determined by the ZFX/ZFY 
and HBB/SRY systems in adult male plasma DNA samples. 
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Figure 6.3 Determination of the fractional fetal DNA concentrations by the 
ZFX/ZFY and HBB/SRY systems in third trimester maternal plasma samples. 
129 
Improvements on maternal plasma analysis of circulating DNA 
6.3.2. Effects of using monoplex and multiplex real-time PCR formulations 
In this part of the study, the relative gene dosages determined by the monoplex and 
multiplex assays were compared. In adult male blood cell samples, the median 
(interquartile range) relative gene dosages determined by the ZFX/ZFY multiplex 
system were 1.03 (0.99-1.08) for the Qiagen assay and 0.97 (0.90-1.01) for the 
Applied Biosystems assay. For the HBB/SRY system, the median (interquartile range) 
relative gene dosages determined by the multiplex assay was 0.99 (0.95-1.17). 
Compared to the data in module 1, no significant difference was observed between 
the relative gene dosages determined by the monoplex and multiplex assays for both 
the ZFX/ZFY the HBB/SRY sysiQms (Figure 6.4). 
In adult male plasma samples, the median (interquartile range) relative gene dosages 
determined by the multiplex system were 0.94 (0.82-1.02) for the Qiagen 
assay and 0.95 (0.84-1.01) for the Applied Biosystems assay. For the HBB/SRY 
system, the median (interquartile range) relative gene dosages determined by the 
multiplex assay was 0.69 (0.60-0.76). The relative gene dosages determined by the 
multiplex assays were significantly closer to the expected value than that determined 
by the monoplex assay for the ZFX/ZFY system (Figure 6.5A). However, for the 
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HBB/SRY system, both monoplex and multiplex assays resulted in underestimations 
of the SRY:HBB ratio (Figure 6.5B). 
In maternal plasma analysis, the median (interquartile range) fractional DNA 
concentrations determined by the ZFX/ZFY multiplex system were 20.9% 
(10.3%-23.5%) for the Qiagen assay and 16.5% (ll.l%-24.3%) for the Applied 
Biosystems assay. For the HBB/SRY system, the median (interquartile range) relative 
gene dosages determined by the multiplex assay was 8.5% (5.1%-12.8%). Generally, 
the monoplex assays and the multiplex assays gave similar performances in the 
determination of the fractional fetal DNA concentrations in maternal plasma (Figure 
6.6). For the ZFX/ZFY system in particular, the fractional fetal DNA concentration 
determined by the multiplex Applied Biosystems assay was significantly lower than 
that determined by the monoplex assay (Figure 6.6A). 
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Figure 6.4 Comparison of the relative gene dosages determined by the monoplex 
and multiplex qPCR assays in adult male blood cell DNA samples. Box plots of (A) 
relative gene dosages analyzed by the ZFX/ZFY system (B) relative gene dosages 
analyzed by the HBB/SRY system. 
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Figure 6.5 Comparison of the relative gene dosages determined by the monoplex 
and multiplex qPCR assays in adult male plasma DNA samples. Box plots of (A) 
relative gene dosages analyzed by the ZFX/ZFY system (B) relative gene dosages 
analyzed by the HBB/SRY system. 
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Figure 6.6 Determination of the fractional fetal DNA concentrations by the 
monoplex and multiplex qPCR assays in third trimester maternal plasma samples. 
Box plots of (A) fetal DNA concentrations determined by the ZFX/ZFY system (B) 
fetal DNA concentrations determined by the HBB/SRY sysXtm. 
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6.3.3. Effects of incorporating calibration curves for template quantification in 
conventional qPCR 
In this part of the study, the relative gene dosages determined by the digital and 
non-digital assays for the ZFX/ZFY system were compared. In adult male blood cell 
samples, the median (interquartile range) relative gene dosage determined by the 
digital assay was 1.04 (0.92-1.12). The accuracy of conventional qPCR analysis was 
comparable to that of dPCR analysis in assessing gene dosages in male blood cells 
(Figure 6.7). 
In adult male plasma samples, the median (interquartile range) relative gene dosage 
determined by the digital assay was 0.89 (0.86-0.98). The non-digital multiplex 
assays and the digital assay showed less deviation from the expected value of 1 than 
the non-digital monoplex assay for gene dosage comparison in male plasma (Figure 
6.8). 
In maternal plasma analysis, the median (interquartile range) fractional fetal DNA 
concentration determined by the digital assay was 22.4% (17.4%-31.7%). The 
non-digital monoplex assay and the digital assays gave similar results in the 
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determination of fractional fetal DNA concentration in maternal plasma (Figure 6.9). 
However, the fractional fetal DNA concentrations determined by the non-digital 
multiplex assays were significantly lower than that determined by the digital assay 
„ (Figure 6.9). 
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Figure 6.7 Comparison of the relative gene dosages determined by the digital 
and non-digital assays in adult male blood cell DNA samples. 
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Figure 6.8 Comparison of the relative gene dosages determined by the digital 
and non-digital assays in adult male plasma DNA samples. 
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Figure 6.9 Determination of the fractional fetal DNA concentrations by digital 
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6.4. DISCUSSION 
Conventional qPCR is the one of the most commonly used technologies for 
quantitative analysis of fetal DNA in maternal plasma. Recently, dPCR has been 
shown to be approximately 3 times more precise than conventional qPCR (Lun et al., 
2008a). It was also reported that dPCR revealed less quantitative bias than 
conventional qPCR in the measurement of fractional concentration of male DNA 
(Lun et al., 2008a). Moreover, the fractional fetal DNA concentration in maternal 
plasma determined by dPCR was approximately 2-fold higher than previously 
determined by conventional qPCR (Lun et al., 2008a). However, there may still be 
room for improvement in the quantitative performance of conventional qPCR. 
In module 1, the effect of using the same and different sets of primers to amplify loci 
on different chromosomes was investigated. In the adult male blood cell samples, 
relative gene dosages determined by the ZFX/ZFY assay, which share common 
primers, showed less quantitative bias than the HBB/SRY assay in measuring 
fractional concentration of male blood cells DNA. This suggests the use of the same 
primer sequences for coamplification of the target genes may reduce the differences 
in the amplification efficiencies of the two assays, thus giving a more accurate 
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con-elation of the measured genes. However, the relative gene dosages determined in 
male plasma were lower than those determined in male blood cells for both the 
ZFX/ZFY and HBB/SRY assays. It has been reported that plasma DNA molecules in 
..healthy individuals are relatively short (Chan et al., 2004). The sizes of the 
amplicons for the ZFX/ZFY and the HBB/SRY assays are 87-bp and 137-bp/lOl-bp, 
respectively. If the plasma DNA molecules were shorter than these amplicon lengths, 
they might not be amplifiable. This portion of unamplifiable DNA molecules may 
explain the lower gene dosages observed in male plasma. In addition, the maternal 
plasma results revealed that the fractional fetal DNA concentration measured by the 
ZFX/ZFY system was approximately 2 times higher than that measured by the 
HBB/SRY system. This data is consistent with that reported by Lun et al. (2008a). 
In module 2, the influence of using monoplex and multiplex assays for qPCR 
analysis was evaluated. For the ZFX/ZFY system, it was demonstrated that 
conventional qPCR performed by the multiplex assays gave results closer to the 
expected gene dosage ratio than the monoplex assay in adult male plasma, possibly 
due to the minimization of assay variation when two assays are combined in a 
multiplex formulation. 
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In module 3, the performances of conventional qPCR and dPCR were compared. In 
all of the adult male blood cells, adult male plasma and maternal plasma samples, 
conventional qPCR was able to yield results that were comparable to those of dPCR. 
Thus, conventional qPCR performed in a multiplex formulation with the use of same 
set of primers could be as good as dPCR in analyzing relative gene dosages. 
Although dPCR is thought to be a more sensitive, accurate and precise platform than 
conventional qPCR, the disadvantage of dPCR is the labor intensiveness of perhaps 
having to perform hundreds to thousands of reactions for one sample. With the 
recent advances in microfluidics technology, such problem was solved by the 
introduction of the automated microfluidics dPCR platform. However, the drawback 
of microfluidics dPCR is the cost of the microfluidics chips. In this study, dPCR 
analysis of one maternal plasma sample consumed one microfluidics chip, which 
cost approximately US$300. Due to its simplicity and high throughput performance 
in analyzing multiple samples simultaneously, conventional qPCR offer a cost 
effective method for gene dosage analysis with accuracy comparable to that of 
dPCR. These findings can facilitate the development of qPCR based detection of 
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fetal chromosomal aneuploidies for NIPD of trisomy pregnancies. 
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CHAPTER 7: DPCR DETECTION OF PATERNALLY INHERITED POINT 
MUTATIONS 
7.1. INTRODUCTION 
Thalassemia is a Mendelian recessive condition, and is the most common 
monogenic disease worldwide (Weatherall, 1997). Thalassemia is ethnic specific, 
meaning it is more common in certain ethnic groups. The prevalence of thalassemia 
is up to 16% in Cypriot populations, 3-14% in Thai populations, 3-8% in India, 
Pakistani, Bangladedeshi and Chinese populations, 0.9% in black Caribbean and 
African populations, but is only 0.1% among northern Europeans (Fucharoen and 
Winichagoon, 1987, Davies et al., 2000, Xu et al., 2004). 
Thalassemia is a group of hematologic disorders caused by defective and 
imbalanced globin production (Leung et al., 2005). The globin peptide chains are the 
building blocks of hemoglobin which carries oxygen throughout the body. The 
ability of hemoglobin to transport oxygen is dependent on its molecular structure 
(Poole, 2003). A normal hemoglobin contains a heme molecule that combines with 2 
pairs of globin chains. The globin chains are alpha (a), beta (p), gamma (y), and 
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delta (5) (Leung et al., 2005). Adult hemoglobin contains mostly hemoglobin A 
(-97%) with minor components of hemoglobin A2 and hemoglobin F (<1%) (Poole, 
2003). Since hemoglobin A is the most common adult hemoglobin, any condition 
affecting the synthesis of hemoglobin A becomes significant. Hemoglobin A is a 
tetramer of 2 a-gobin chains and 2 p-goblin chains. The production of a-chains is 
under the control of 4 genes on chromosome 16，while the |3-chain production relies 
on 2 genes on chromosome 11 (Poole, 2003). There are more than 80 mutations in 
the a-gobin genes that cause a-thalassemia, with the majority of mutations being 
gene deletions and small number of point mutations (Old, 2003). On the other hand, 
P-thalassemia can be caused by more than 200 mutations in the HBB gene 
(Weatherall, 2004). The majority of the mutations are point mutations or 
deletions/insertions of just one or two nucleotides (Dimovski et al., 1993). In 
addition, the extent of disruption caused to the globin chain synthesis pathway 
determines the type and severity of the thalassemia (Poole, 2003). 
In this part of my thesis, I shall demonstrate the potential of maternal plasma DNA 
analysis for NIPD of P-thalassemia. The reasons that I have chosen to study 
P-thalassemia were: 1) high frequency of potentially affected pregnancies in the 
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local, 2) the mutations were well characterized, and 3) the mother and the father 
often carried different mutations, and hence studies could be designed to focus on 
the detection of the paternally inherited fetal mutant allele in maternal plasma (Hahn 
and Chitty, 2008). 
p-thalassemia can be classified into 4 types, namely thalassemia minor, thalassemia 
intermedia, thalassemia major, and Hemoglobin E (HbE) thalassemia (Rund and 
Rachmilewitz, 2005). For the development of thalassemia minor, a fetus has to 
inherit a mutation from one of the parents. To develop thalassemia intermedia, a 
fetus has to inherit two mutations, one of which being a mild mutation. Thalassemia 
major is caused by fetal inheritance of two severe mutations from both parents. 
Finally, the inheritance of one mild or severe thalassemia mutation in combination 
with a HBB gene carrying the HbE point mutation will lead to the development of 
HbE thalassemia. The HbE mutation is caused by a G -> A missense mutation in 
codon 26 on the HBB gene. The syndromes of P-thalassemia range from 
asymptomatic in thalassemia minor to severe anemia that requires lifelong 
transfusions and iron chelation therapies in thalassemia major (Rund and 
Rachmilewitz, 2005). 
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In Hong Kong, carriers of p-thalassemia mutations including that coding for HbE 
accounted for 3.4% of the population (Lau et al., 1997). It is estimated that there are 
80 pregnancies per year in Hong Kong in which the fetus is at risk for p-thalassemia 
major or intermedia (Lau et al.，1997). Currently, ultrasound screening has no value 
for the diagnosis of (3-thalassemia major (Leung et al., 2005). With the annual cost 
of treatments for one patient with p-thalassemia major being US$30,000 (Lau et al., 
1997), P-thalassemia remains a serious physical, emotional, and financial burden for 
potential parents. 
In 2002, Chiu et al demonstrated noninvasive prenatal exclusion of P-thalassemia 
major by using allele specific qPCR to detect the fetal inheritance of a paternally 
derived mutation, a four nucleotide deletion of CTTT at codons 41/42, which 
accounts for 40% of all p-thalassemia in Hong Kong (2002b). Since majority of 
p-thalassemia are caused by point mutations rather than deletions, the qPCR 
approach was then applied to the detection of fetal p-thalassemia point mutations in 
maternal plasma. However, it was soon proven to be difficult due to the lack of 
absolute specificity of allele specific primers (Nasis et al., 2004). It is believed that 
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qPCR is generally not robust enough to detect a minority nucleic acid population 
which differs from the majority background by a single nucleotide, as nonspecific 
signal generation from the wild type allele may occur (Gibson, 2006). In addition, 
the requirement for sufficient fluorescence signals to reach a certain threshold before 
a positive detection can be scored is a major limitation of the qPCR platform for 
analysis of nucleic acids in low abundance (Hung et al., 2009). 
In 2004, a MS based method was evaluated for its application in excluding fetal 
inheritance of the 4 most common P-thalassemia point mutations (CD41/42, IVS2 
654, nt-28 & CD17) among Southeast Asians (Ding et al., 2004). MS is an analytical 
technique that measures the mass-to-charge ratio of an ion with resolution down to a 
few daltons. Using this high resolution platform, single allele base extension 
reaction (SABER) was developed as a method for the detection of 4 fetal 
P-thalassemia point mutations in maternal plasma (Ding et al., 2004). In a 
proof-of-principle experiment, Li et al. exploited the physical size difference 
between maternal and fetal DNA for the selective enrichment of fetal DNA 
molecules to detect fetal DNA polymorphisms in maternal plasma (2004b). Using 
size fractionated circulating DNA; detection of paternally inherited fetal point 
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mutations for P-thalassemia was demonstrated (Li et al., 2005). In 2005, a 
specialized PCR technique using a peptide nucleic acid clamp specific for the 
maternal allele was developed for the suppression of unwanted amplification of this 
allele during the PCR process (Li et al., 2005). The efficacy of this approach for 
NIPD of P-thalassemia was explored in a large-scale study in SAFE in 2006. 
Preliminary data showed that the peptide nucleic acid mediated mutant enrichment 
amplification was very promising, indicating that this method, when optimized, 
could be coupled with microchip technologies and pyrosequencing systems (Galbiati 
et al., 2006). In the same year, the combined use of size fractionation and MS was 
demonstrated using a SNP model system to mimic the scenario occurring in 
thalassemias (Li et al., 2006). In a preliminary study, Papasawa el al. investigated 
two different approaches, namely allele-speciflc PCR and arrayed primer extension 
method, in the detection of paternally inherited SNP as well as p-thalassemia 
mutations in maternal plasma. The detection of paternally inherited allele in 
maternal plasma was demonstrated for three SNPs using allele-specific PCR. 
Moreover, the arrayed primer extension method was shown to be able to detect very 
low DNA copy number. However, the reaction needed further optimization to be 
able to detect fetal DNA in maternal plasma (2006). In 2007, the SABER approach 
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was applied to the NIPD of the HbE disease, which when inherited with a 
p-thalassemia mutation will result in severe anemia (Tsang et al., 2007). 
Unexpectedly, SABER could not be applied to the detection of HbE due to the lack 
of specificity discovered during assay development. Therefore, an alternative 
approach, allele specific base extension reaction (ASBER) was developed with a 
specificity of 100% and a sensitivity of 80% in detecting the HbE mutation in 
maternal plasma (Tsang et al., 2007). In 2008, Lun et al. described a digital relative 
mutation dosage approach, which based on the quantitative discrimination of small 
imbalances in concentrations between the mutant and wild type alleles in maternal 
plasma. In combination with a digital nucleic acid size selection strategy that 
selectively enriches the fetal DNA in maternal plasma, noninvasive assessment of 
maternally inherited fetal p-thalassemia mutation was finally achieved (2008b). 
Noninvasive detection of single nucleotide changes requires highly sensitive and 
specific analytical platform coupled with stringent assays that permit a clear 
discrimination between normal and mutant alleles. Current methods, such as qPCR 
and MS, are not 100% sensitive and specific in detecting the minor population of 
fetal DNA that differs from background maternal DNA by a single nucleotide (Ding 
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et al., 2004, Tsang et al., 2007). Furthermore, the reported method for size 
fractionation relies on the size separation of plasma DNA using agarose gel 
electrophoresis, followed by the extraction of DNA from gel slices containing 
different size fractions. This method not only is prone to contamination, but also 
leads to considerable loss of genetic material. While the fraction of fetal DNA may 
be enriched, the absolute amount of DNA is reduced. Therefore, a new and robust 
method must be developed for noninvasive detection of single nucleotide differences 
in maternal plasma. 
The operation of dPCR relies on physical separation of nucleic acids into discrete 
units as described in Chapter 4.4.1. Operating at single molecule concentrations, 
dPCR allows analysis of the fetal and maternal DNA separately. I hypothesized that 
due to this physical separation, the background wild type molecules derived from 
the mother would not interfere with the fetal derived target molecules, thus offering 
improved sensitivity and specificity in assessing fetal inheritance of paternally 
inherited point mutations in maternal plasma. Thus, in this part of the thesis, I 
further extend the use of dPCR for maternal plasma detection of paternally inherited 
fetal HbE mutation for NIPD of hemoglobinopathies. 
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12. MATERIALS AND METHODS 
7.2.1. Study design 
To investigate maternal plasma detection of paternally inherited HbE mutation in 
maternal plasma, this study composed of three modules. The first module (module 1) 
involved the validation of the dPCR assay. The second module (module 2) studied 
the limit of detection of dPCR. The third module (module 3) evaluated the 
performance of dPCR in detecting paternally inherited HbE mutation in maternal 
plasma. 
Module 1: 
To evaluate the specificity of the dPCR assay, different types of samples, including 
diluted genomic DNA, adult male plasma DNA and genomic DNA mixtures, were 
used for preliminary assay validation. After the assay was partially validated, 10 
second trimester maternal plasma samples from healthy pregnancies were recruited 
for the final validation of the assay specificity before it was subjected to maternal 
plasma analysis. 
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Module 2: 
Prenatal exclusion of HbE disease or p-thalassemia can be achieved by maternal 
plasma detection of the presence or absence of the paternally inherited mutations. 
However, to conclude the absence of mutations, one must face the challenge of 
interpreting negative results. 
A negative result for the detection of paternal mutant alleles in maternal plasma can 
be interpreted in the following ways: 1) the fetus has not inherited the mutation from 
the father, indicating the exclusion of the inheritance of the disease, 2) DNA is 
absent in the reaction due to too little input DNA, which can be confirmed by 
checking the wild type allele, or 3) fetal DNA is absent in the reaction due to low 
amount of the fractional fetal concentration, which requires additional analysis to 
confirm the presence of fetal DNA and to determine the actual fetal DNA percentage 
in maternal plasma. For the above reasons, one must address the sensitivity of a 
potential diagnostic test before it can be applied to maternal plasma analysis. 
The analytical sensitivity of a dPCR assay is dependent on the minimum input 
amount of DNA for a dPCR analysis. In this module, I investigated the minimum 
154 
Improvements on maternal plasma analysis of circulating DNA 
fetal DNA copies per digital PCR panel of 384-wells that can be detected with 95% 
certainty. In other words, what is the minimum number of fetal DNA molecules 
required for each dPCR run to yield a positive detection of the fetal molecules for 
95% of the time? To answer this question, I created a mathematical model (Table 
7.1). In the model, m = 0.5 was set as the sample concentration, where m is the 
average number of template molecules per well in a particular digital PCR 
experiment, meaning approximately 192 DNA molecules are present in a 384-well 
digital panel. I then prepared genomic DNA mixtures to contain 1, 3 or 5 mutant 
molecules among the total of 192 DNA molecules. These genomic DNA mixtures 
were then subjected to 10 dPCR analyses to determine if the mutant molecules could 
be detected 95% of the time. 
After the determination of the minimum fetal DNA copies required for dPCR 
detection, the information was used to determine the minimum input amount of 
DNA for the analysis performed in module 3. 
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Table 7.1 Genomic DNA mixtures compiled to investigate the minimum 
number of fetal DNA required for dPCR detection. 
# o f # o f Equivalent % % 
Expected # of 
mutant wild type Fetal DNA ^m negative positive 
positive wells 
molecules molecules % wells wells 
1 191 1.04% 0.50 60.65% 39.35% 151 
3 189 3.13% 0.50 60.65% 39.35% 151 
5 187 5.21% 0.50 60.65% 39.35% 151 
Total number of wells per digital panel = 384 
^m is the average concentration of template molecules per well 
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Module 3: 
In this module, 30 maternal plasma samples were analyzed by the digital HbE assay 
for diagnosis of the fetal HbE mutation status. Fetal genotypes determined by dPCR 
analysis were compared with those obtained by conventional prenatal diagnostic 
procedures. 
7.2.2. Subjects and sample collection 
Peripheral blood samples were collected before invasive procedures from couples 
presenting for prenatal diagnosis of p-thalassemia or HbE disease with informed 
consent from the Chiang Mai University, Thailand. Fetal cord blood was collected in 
the second trimester of pregnancy during cordocentesis, which is the standard 
prenatal diagnostic procedure offered locally. 
Peripheral blood samples were collected from healthy pregnant women in second 
trimester pregnancies with informed consent at the Department of Obstetrics and 
Gynaecology, Prince of Wales Hospital, Hong Kong. 
Peripheral blood samples were collected from healthy adult males with informed 
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consent at the Department of Chemical Pathology, Prince of Wales Hospital, Hong 
Kong. 
Peripheral blood samples recruited from Thailand were processed by the Chiang Mai 
University. Peripheral blood samples collected in the Prince of Wales Hospital were 
processed according to the procedures described in Chapter 4.1. The study was 
approved by the Joint CUHK-NTEC Clinical Research Ethics Committee. 
7.2.3. DNA extraction and sample preparation 
Genomic DNA was extracted from maternal, paternal, fetal and adult male blood 
cells with the protocol described in Chapter 4.2.2.2. For adult male and maternal 
plasma samples, DNA was extracted according to the protocol described in Chapter 
4.2.1.2. The genomic DNA concentration for each blood cell sample was measured 
® 
by the NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies) 
before being diluted for dPCR analysis. Genomic DNA mixtures comprised of a 
minor population of mutant molecules in a background of wild type molecules were 
prepared by mixing blood cell DNA from subjects homozygous for the wild type 
and the mutant alleles, respectively. 
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7.2A. MassArray hME assays 
Maternal and paternal genotyping was performed on the genomic DNA obtained 
from the maternal and paternal blood cell samples. Fetal genotyping was performed 
on the genomic DNA obtained from the fetal cord blood cell samples. Genotyping of 
the HbE mutation was done using MassARRAY hME assays (Sequenom) as 
described in Chapter 4.5.2. The development of the hME assay for the HbE mutation 
was described previously (Tsang et al., 2007). 
7.2.5. dPCR assay 
dPCR assays were developed in a duplex format to target the HbE locus using 
allele-specific TaqMan MGB probes (Applied Biosystems) to discriminate the wild 
type and the mutant alleles. 
The sequences of the primers (Integrated DNA Technologies) were 
5'-GGGCAAGGTGAACGTGGAT-3' (sense) and 
5丨-CTATTGGTCTCCTTAAACCTGTCTTGTAA-3丨(antisense). The probe (Applied 
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Biosystems) sequence for the wild type allele was 5'-(VIC) TTGGTGGTGAGGCC 
(MGB)-3'. The probe (Applied Biosystems) sequence for the mutant allele was 
5丨-(FAM) TTGGTGGTAAGGCC (MGB)-3丨. 
dPCR reactions were set up with components provided in the TaqMan Universal 
PCR Master Mix Kit (Applied Biosystems). The final concentrations of the primers 
and probers were 300 nM and lOOnM, respectively. dPCR analysis was applied to 
the second trimester maternal plasma samples collected from couples where the 
fathers were HbE carriers while the mothers were normal for the HbE mutation. All 
dPCR analyses in this study were set up using the Micro Amp® Optical 3 84-Well 
Reaction Plates (Applied Biosystems) and performed on the ABI 7900HT Fast 
Real-Time PCR System (Applied Biosystems). 
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7.3. RESULTS 
7.3.1. Validation of the digital HbE assay 
For preliminary validation of the digital HbE assay, different types of samples were 
used, including 4 plasma samples of males homozygous for the wild type allele, 1 
genomic DNA sample of a pregnant woman homozygous for the mutant allele, 1 
genomic DNA sample of a heterozygous pregnant woman, 2 genomic DNA mixtures 
comprised of 5% and 20% mutant molecules, and a negative control composed of 
water. Results are listed in Table 7.2. For all the homozygous wild type cases, no 
mutant molecules were detected. Similarly, no wild type molecule was detected in 
the homozygous mutant sample. Moreover, no target was detected in the negative 
control, indicating no nonspecific amplification due to mispriming or primer dimers 
was caused by the assay design. For the heterozygous sample, the wild type and the 
mutant alleles had similar counts, suggesting the assay showed no bias in the 
amplification of either allele. Finally, mutant molecules were detectable in both 5% 
and 20% genomic DNA mixtures, strengthening the possibility of detecting DNA of 
minor population in maternal plasma by digital PGR. 
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Since NIPD of the HbE disease relies on the qualitative detection of the fetal mutant 
allele in maternal plasma, any nonspecific amplification of the wild type allele 
would yield the wrong diagnosis. Therefore, the specificity of the digital HbE assay 
„ was further validated using 10 second trimester maternal plasma samples from 
healthy pregnant women homozygous for the wild type allele. In all 10 maternal 
plasma cases, no mutant molecule was detected (Table 7.3). In both rounds of 
validation, the digital HbE assay showed 100% specificity with no nonspecific 
detection. 
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Table 7.2 Digital PGR analysis of various samples for assay validation. 
Wild type Mutant % Mutant / 
Sample type Genotype 
count count Total 
Adult male plasma DNA Homozygous 45 0 0 
#1 wild type 
Adult male plasma DNA Homozygous 
#2 wild type 
Adult male plasma DNA Homozygous ^^^ 。 。 
#3 wild type •• 
Adult male plasma DNA Homozygous 89 0 0 
#4 wild type 
Homozygous 
Maternal blood cells DNA 0 157 100% 
mutant 
Maternal blood cells DNA Heterozygous 94 87 48.1% 
Genomic DNA mixture 20% mutant 143 45 23.9% 
Genomic DNA mixture 5% mutant 143 4 2.7% 
Distilled water No allele 0 0 N/A 
Total number of wells per digital PGR panel = 384 
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Table 7.3 Digital PCR analysis of second trimester maternal plasma samples 
from healthy pregnant women. 
Sample ID Wild type count Mutant count 
M5402 100 0 
M5403 250 0 
M5410 230 0 
M5445 124 0 
M5446 101 0 
M5447 204 0 
M5459 187 0 
M5470 174 0 
M5473 141 0 
M5503 223 0 
Total number of wells per digital PCR panel = 384 
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7.3.2. Determination of the minimum fetal DNA amount required for digital PCR 
detection 
To determine the minimum fetal DNA amount required for each 384-well dPCR 
analysis, genomic DNA mixtures containing 1, 3 and 5 mutant molecules in a 
background of wild-type molecules were prepared (Table 7.1). To achieve a positive 
detection at 95% certainty, the digital HbE assay must reveal at least one well 
positive for the mutant allele in the DNA mixtures in each of the 10 analyses. I 
started off with the DNA mixture containing 1 mutant molecule, and then as soon as 
a negative result was generated, I moved on the next DNA mixture containing more 
mutant molecules until positive detection of the mutant molecule was achieved in 10 
digital PCR analyses. Results are listed in Tables 7.4, 7.5 and 7.6. Using the DNA 
mixture containing 5 mutant molecules, positive detection of the mutant allele was 
achieved in all 10 digital PCR runs. Among these 10 runs, the average number of 
mutant fetal molecules per plate was 4.40 copies. This information will be used to 
guide the maternal plasma DNA extraction protocol to be adopted for fetal DNA 
detection by dPCR. 
First, I reviewed the known information regarding the fractional fetal concentrations 
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in early pregnancy. According to Lun et al., fractional fetal concentration in 
first-trimester maternal plasma ranges from 5.7% to 17.3% (2008a). To ensure that 
adequate fetal DNA molecules are available for dPCR analysis even in pregnancies 
with low fetal DNA concentration, I calculated the volume of DNA needed to give at 
least 10 paternally inherited fetal DNA molecules (i.e. 2 times the minimum fetal 
DNA amount required for each digital PCR analysis as determined previously) in 
maternal plasma samples with 5.7% fetal DNA. To do that, four maternal plasma 
samples from women pregnant with male fetuses were selected within the same 
cohort as the HbE cases. The amounts of the maternal and fetal DNA in these 
samples were quantified using the ZFX/ZFY qPCR assay (Table 7.7). Since dPCR 
operates at single molecule concentrations, it is also essential that the total number 
of DNA molecules analyzed in each run does not exceed the number of wells 
available in the digital PCR panel. The median concentration of total DNA 
molecules {ZFX plus ZFY) in the maternal plasma samples was 1460 copies per 
milliliter of plasma. Using this median, the minimum input volume of maternal 
plasma DNA was calculated using the following formula: 
V input DNA = 1 0 / % fetal X ( V d n a / V ext) / C Total 
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where V input dna = volume of input DNA (jiL); % fetal = the minimum fractional fetal 
concentration in first trimester pregnancies (5.7%); V d n a = total volume of DNA 
obtained after extraction (50 fiL); V ext = volume of plasma extracted (800 p.L); C 
Total = median concentration of total DNA molecules in maternal plasma (1460 
copies per milliliter). 
Using this formula, an input volume of 7.5 |iL DNA would give 10 paternally 
inherited fetal DNA molecules in maternal plasma samples with 5.7% fetal DNA 
while maintaining the m at approximately 0.5 (i.e. 1 DNA molecule would be 
present in 2 reaction wells in a 384-well digital PCR panel). Thus, this volume was 
used as the input volume of DNA for dPCR analysis of the maternal plasma samples 
in module 3. 
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Table 7.4 Digital PCR analysis of genomic DNA mixtures containing one 
mutant molecule. 
Mutant Wild-type rr . • ‘ ‘ •。, 
Plate ID m Equivalent Fetal % 
count count 
1 1 148 0.49 1.06% 
2 0 143 0.47 0.00% 
mean 0.48 0.53% 
Total # of analyses 2 
% plates with 
50% 
positive detection 
Total number of wells per digital panel = 384 
^m is the average concentration of template molecules per well 
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Table 7.5 Digital PCR analysis of genomic DNA mixtures containing three 
mutant molecules. 
Mutant Wild-type , 「 . ，，「，•。， 
Plate ID m Equivalent Fetal % 
count count 
1 3 137 0.45 3.49% 
2 1 148 0.49 1.06% 
3 2 171 0.59 1.75% 
4 1 137 0.44 1.18% 
5 2 137 0.45 2.34% 
6 1 155 0.52 1.01% 
7 0 122 0.38 0.00% 
mean 0.47 1.55% 
Total # of analyses 7 
% plates with 
86% 
positive detection 
Total number of wells per digital panel = 384 
••"m is the average concentration of template molecules per well 
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Table 7.6 Digital PGR analysis of genomic DNA mixtures containing five 
mutant molecules. 
Mutant Wild-type . .。， 
Plate ID rn Equivalent Fetal % 
count count 
1 4 133 0.43 4.79% 
2 2 149 0.5 2.09% 
3 4 144 0.48 4.35% 
4 4 143 0.48 4.37% 
5 9 164 0.58 8.07% 
6 2 147 0.49 2.14% 
7 3 140 0.46 3.39% 
8 3 121 0.39 4.05% 
9 7 150 0.51 7.11% 
10 6 146 0.49 6.32% 
mean 0.48 4.67% 
Total # of analyses 10 
% plates with 
100% 
positive detection 
Total number of wells per digital panel = 384 
卞m is the average concentration of template molecules per well 
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Table 7.7 Quantification of ZFXand ZFYDNA in maternal plasma samples for 
the determination of the minimum amount of DNA input for dPCR detection. 
ZFX ZFY Total 
Case Fetal % 
(Copies I mL plasma) 
CMU11 1630 49 1679 5.8% 
CMU24 1201 35 1236 5.6% 
CMU29 1863 68 1931 7.0% 
CMU49 844 107 951 22.5% 
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7.3.3. Detection of paternally inherited fetal HbE mutation in maternal plasma 
The digital HbE assay was applied to digital PCR analysis of 30 maternal plasma 
samples. Results were generated by direct counting of the wells with positive 
amplification of the target allele and are listed in Table 7.8. These results were 
compared with the fetal genotypes obtained from invasive testing for concordance 
(Table 7.8). MS analysis revealed that out of the 30 cases analyzed, 11 fetuses 
inherited the HbE mutation from the fathers, while 19 fetuses did not exhibit 
inheritance of the paternal mutations. With dPCR analysis of maternal plasma, I was 
able to correctly classify the fetal genotypes in 28 of the 30 cases. Two false positive 
cases (CMU73 & CMU80b) were observed in the study. The fetal genotypes of 
these 2 cases were reconfirmed with MS analysis. For both cases, DNA was 
reextracted from the maternal plasma and reanalyzed by dPCR (Table 7.8). However, 
false positive results persisted in the newly reextracted maternal plasma DNA. To 
investigate the underlying cause of the false positive results, wells that were scored 
positive for the mutant allele were subjected to cloning and sequencing. Sequencing 
data revealed that genuine mutant molecules were present in both false positive 
samples. These results could either be caused by contamination or sample mixing. 
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Table 7.8 HbE mutation detection in maternal plasma samples by dPCR. 
Wild type Mutant 十 Fetus diagnosis Fetus diagnosis 
Sample ID Total ^m 
count count by digital PCR by MS 
CMU8 204 0 204 0.76 no HbE no HbE 
CMU9 164 16 180 0.60 HbE carrier HbE carrier 
CMU12 199 0 199 0.73 no HbE no HbE 
CMU13 211 0 211 0.80 no HbE no HbE 
CMU14 174 9 183 0.63 HbE carrier HbE carrier . 
CMU15 107 0 107 0.33 no HbE no HbE 
CMU17 85 0 85 0.25 no HbE no HbE 
CMU22 131 0 131 0.42 no HbE no HbE 
CMU23 169 0 169 0.58 no HbE no HbE 
CMU26 122 9 131 0.41 HbE carrier HbE carrier 
CMU27 109 0 109 0.33 no HbE no HbE 
CMU32 173 0 173 0.60 no HbE no HbE 
CMU40 75 7 82 0.23 HbE carrier HbE carrier 
CMU51 148 3 151 0.49 HbE carrier HbE carrier 
CMU57 127 0 127 0.40 no HbE no HbE 
CMU58 190 13 203 0.72 HbE carrier HbE carrier 
CMU60 147 0 147 0.48 no HbE no HbE 
CMU63 183 8 191 0.67 HbE carrier HbE carrier 
CMU65 139 0 139 0.45 no HbE no HbE 
CMU72 244 7 251 1.03 HbE carrier HbE carrier 
CMU73 221 2 223 0.86 HbE carrier no HbE 
CMU73# 307 1 308 1.61 HbE carrier no HbE 
CMU76 82 5 87 0.25 HbE carrier HbE carrier 
CMU78 261 0 261 1.14 no HbE no HbE 
CMU80a 195 0 195 0.71 no HbE no HbE 
CMU80b 212 4 216 0.81 HbE carrier no HbE 
CMU80b# 223 2 225 0.88 HbE carrier no HbE 
CMU81 299 0 299 1.51 no HbE no HbE 
CMU89 ‘ 197 12 209 0.75 HbE carrier HbE carrier 
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Table 7.8 HbE mutation detection in maternal plasma samples by dPCR. 
(Continued) 
Wild type Mutant 十 Fetus diagnosis Fetus diagnosis 
Sample ID Total 卞m ^ 
count count by digital PCR by MS 
CMU91 182 0 182 0.64 no HbE no HbE 
CMU94 s 0 228 0.9 no HbE no HbE 
CMU97 141 5 146 0.47 HbE carrier HbE carrier 
Total number of wells per digital panel = 384;卞m is the average concentration of template molecules per well. 
# Samples reextracted and reanalyzed. 
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7A. DISCUSSION 
NIPD of p-thalassemia and HbE disease typically relies on the qualitative detection 
or exclusion of the paternal mutations in maternal plasma. However, maternal 
plasma detection of paternally inherited mutation has been technically challenging 
due to the coexistence of fetal DNA and maternal DNA in maternal plasma (Chiu et 
al., 2009). The combination of high level of maternal background DNA and low 
level of fetal target DNA in maternal plasma may interfere with the detection of 
these fetal mutations (Hung et al., 2009). This problem is further complicated by the 
fact that most of the disease causing mutations for p-thalassemia are point mutations 
(Dimovski et al., 1993). The detection of single nucleotide differences was proven to 
be difficult by the current methods used for maternal plasma analysis, such as qPCR 
and MS (Ding et al., 2004, Tsang et al” 2007). 
Since digital PGR operates at single molecule concentrations, where the interference 
of the fetal DNA molecule from the background maternal DNA would be minimal, 
this approach is expected to offer improved sensitivity and specificity in the 
detection of paternally inherited point mutations in maternal plasma. Indeed, allelic 
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discrimination between the wild type and the mutant alleles was achieved in various 
samples using dPCR. The assay was also confirmed to be specific for the detection 
of HbE. Using dPCR analysis, NIPD of HbE disease was demonstrated in maternal 
plasma. Fetal genotypes for the HbE mutation were correctly classified in 28 of the 
30 cases. However, two false-positive cases were also noted. The sequencing results 
revealed that genuine mutant molecules were present in both cases, most likely due 
to a minor contamination or swapping of maternal plasma samples. There was no 
evidence that the false positive results were caused by any nonspecific activities of 
the digital HbE assay. Together, digital PCR showed a sensitivity of 100% and a 
specificity of 90% for noninvasive detection of the HbE mutation in maternal 
plasma. Further study is needed to extend this application to other p-thalassemia 
point mutations. 
Digital PCR analysis is a robust technique for the qualitative detection of fetal DNA 
in maternal plasma. It was demonstrated in this study that the minimum fetal DNA 
amount required for a digital analysis of 384-wells was 5 copies. It has been 
reported that the mean quantity of cell-free fetal DNA in early gestation is 25 GE per 
one milliliter of maternal plasma (Lo et al., 1998b). Therefore, even at low fractional 
concentrations of 5.7%, one can still easily obtain 5 fetal DNA molecules from one 
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milliliter of maternal plasma. These findings suggest that digital PCR is more than 
sensitive enough to detect the fetal DNA in maternal plasma during the 
first-trimester pregnancy, showing tremendous potentials for the development of 
earlier NIPD. However, the limitation of digital PCR analysis is the number of PCR 
reactions that can be set up within one digital panel. In this study, 384-wells optical 
plates were used for the digital PCR analysis of all the samples. With the main 
feature of digital PCR being single molecule amplification, it was essential that only 
a single template molecule was to be present in each of the 384-wells for each 
analysis. Thus, a maximum of 384 DNA molecules could be analyzed by each 
digital PCR analysis of 384-wells. According to the Poisson's distribution, at an 
average concentration of 1 molecule per well, the expected proportion of wells 
contain no molecule was 0.37. In another word, 63% of the reaction wells would 
contain one or more template molecules. The presence of two template molecule per 
well would defeat the purpose of digital analysis and might cause nonspecific 
detection of the wrong allele. Therefore, all the digital PCR analysis in this study 
was targeted at 衍二 0.5，meaning there would be on average one template molecule 
per two reaction wells, reducing the probability of having more than one allele in 
each PCR reaction. Allowing single molecule amplification, digital PCR offered 
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• 
improved sensitivity and specificity in the detection of DNA of minor population. 
However, such advantages came with a price. As mentioned before，all digital PGR 
analyses in this study were targeted at m = 0.5, meaning only approximately 192 
DNA molecules were to be input in each analysis. To accommodate this requirement, 
dilution was performed in some samples to adjust the amount of input DNA. 
However, this action may become problematic for maternal plasma analysis, as any 
dilution of the maternal plasma may further dilute the fetal DNA concentration, thus 
requiring additional analyses to rule out the possibility of false negative results. The 
labor intensiveness of performing additional analyses of hundreds or thousands PGR 
reactions may discourage one to choose such a method for maternal plasma analysis. 
However, with the recent development of the microfluidics technology, automation 
of dPCR analysis may overcome such a problem. 
Digital relative mutation dosage analysis developed by Lun et al. allows the 
assessment of maternally inherited fetal mutation if both the mother and the father 
carry the same P-thalassemia mutation. However, if the mother and the father carry 
different mutations, this approach would only determine if the fetus is a carrier for 
the maternal mutation. For prenatal exclusion of a compound heterozygote, 
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detection of the paternally inherited mutation is still essential. Therefore, the use of 
digital PCR for qualitative detection of the paternally inherited mutation in maternal 
plasma, coupled with digital relative mutation dosage analysis of the maternally 
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CHAPTER 8: CONCLUSION AND FUTURE PERSPECTIVES 
8.1. IMPROVEMENTS ON QUANTITATIVE AND QUALITATIVE ANALYSIS OF 
FETAL NUCLEIC ACIDS IN MATERNAL PLASMA 
Since the discovery of circulating fetal nucleic acids in maternal plasma, 
noninvasive prenatal diagnosis was made possible by maternal plasma analysis.. 
Maternal plasma nucleic acid analysis was described for NIPD of various 
pregnancy-associated conditions, including PET, preterm labor, and fetal trisomies. 
However, the clinical applications of these methods are limited by the technical 
challenges associated with maternal plasma nucleic acid analysis. As a result, 
researchers have looked into different possibilities to improve the qualitative and 
quantitative analysis of fetal nucleic acids in maternal plasma. 
Placental mRNA markers have shown potential in maternal plasma analysis as they 
are applicable to all pregnancies independent of the fetal sex. However, the low 
abundance of placental mRNA in maternal plasma has created difficulties for 
potential assay developments. In chapter 5, enrichment of placenta expressed mRNA 
markers by whole transcriptome preamplification was described. Preamplification of 
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placental tissue and maternal plasma RNA samples were shown to be able to 
partially increase the absolute concentrations of placental transcripts, improving the 
delectability of placental mRNA markers for quantitative analysis. 
Gene dosage comparison by quantitative analysis of circulating fetal DNA in 
maternal plasma has been widely used for the assessment of allelic imbalances in the 
fetal genome for NIPD of chromosomal aneuploidies. However, inaccurate 
measurements of gene dosages in maternal plasma by conventional qPCR may lead 
to misdiagnosis. In Chapter 6, accurate gene dosage comparison by multiplex qPCR 
was demonstrated. Conventional qPCR performed in a multiplex formulation with 
the use of a same set of primers for coamplification of the target sequences, can be 
as good as digital PCR in analyzing relative gene dosages in maternal plasma. With 
this improvement, conventional qPCR represents a cost effective method for gene 
dosage comparison for NIPD of chromosomal aneuplodies. 
Qualitative detection of the presence or absence of the paternally inherited mutations 
in maternal plasma can confirm or exclude the fetal inheritance of autosomal 
recessive diseases, including hemoglobinopathies, congenital adrenal hyperplasia, 
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and cystic fibrosis. However, current technologies, such as conventional qPCR and 
MS, lack absolute sensitivity and specificity in the maternal plasma detection of 
paternally inherited alleles. In Chapter 7, dPCR was shown to be a robust method in 
detecting paternally inherited HbE mutation in maternal plasma. Prenatal diagnosis 
of the fetal inheritance of the HbE disease was achieved by digital PGR analysis 
with a sensitivity of 100% and a specificity of 90%. 
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8.2. PERSPECTIVES FOR FUTURE WORK 
The evaluation of the preamplification technology described in Chapter 5 revealed 
that enrichment of the placental mRNA markers was possible in both placental tissue 
and maternal plasma samples. However, uniform amplification could not be 
achieved for the entire transcriptome as enrichment was only observed in the highly 
expressed mRNA markers, and not in transcripts of low abundance. This problem 
was particularly highlighted in the preamplification of maternal plasma because 
partial enrichment of the placenta expressed mRNA markers was observed. 
Therefore, further work is needed in the optimization of the technology in order to 
truly achieve whole transcriptome amplification. 
The investigation of gene dosage comparison by multiplex qPCR in Chapter 6 
showed that quantitative measurements of gene dosages using conventional qPCR 
coupled with multiplex qPCR assays could yield results comparable to that of dPCR. 
However the multiplex assays used in this study were duplex assays. Further work is 
needed to evaluate the performance of multiplex qPCR for more complex 
applications. For example, further work is needed to evaluate the accuracy of 
multiplex qPCR for the maternal plasma detection of chromosomal aneuploidies, 
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such as T21, trisomy 18, and trisomy 13. 
The development of dPCR analysis of fetal inheritance of the paternally- inherited 
HbE mutation in maternal plasma as described in Chapter 7, demonstrated that 
dPCR is a robust method for the qualitative detection of paternal alleles in maternal 
plasma. By analyzing the fetal DNA and the maternal background DNA molecules 
separately, dPCR was able to detect the paternally inherited mutant alleles in all of 
the maternal plasma samples from women pregnant with heterozygous HbE fetuses. 
With the success shown in the dPCR detection of the HbE mutation, further 
investigation is needed to extend the applications of this technical to other 
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